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ABSTRACT
The total population of diagnosed and undiagnosed diabetes mellitus in the United
states is expected to rise by 54% between the years of 2015 and 2030 contributing to $200
billion in health care expense. The exponential rise in common diabetic wounds, such as
diabetic foot ulcers, puts a large population at risk for complications such as infection,
amputation, and even death. Peripheral neuropathy leading to late diagnoses, patient noncompliance, and lack of holistic treatment options all contribute to complications with the
incidence of new ulcer formation after treatment reaching 50%. This work explores the
design, development, and in vitro evaluation of a multicomponent textile-based biomaterial
and absorptive dressing that combines the need to manage infection, eliminate excess
exudate levels, and provide an ideal environment for healthy tissue to repair and remodel
the wound site.
Melt-splun poly-l-lactide (PLLA) yarn of fibers with round or 4-deep-grooved
(4DG) geometry were knitted into the skin-contact layer, the first layer of the dressing.
Different methods of gentamicin sulfate (GS) incorporation, along with the impact of fiber
geometry, were studied to explore optimal antibiotic release and efficacy. Results indicated
that an increase in surface area as well as heat-enabled diffusion allowed for higher release
of GS. Because each factorial treatment, with the exception of exhaustion dyeing method
of incorporation, released GS at or above the minimum inhibitory concentration, there
showed no difference in geometry and method of incorporation on antibacterial efficacy.
The GS incorporated skin contact layer also appeared to be biocompatible in cultures of
mouse bone marrow stromal D1 cells. Cell adhesion study showed that a polyethylene
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glycol (PEG) surface treatment is needed to prevent non-specific protein and cellular
attachment upon dressing changes. A microscopically thin layer of PEG was added to the
surface of the contact layer and showed less cell attachment as seen in fluorescently labeled
LIVE/DEADTM analysis, while showing no impact on GS release and antibacterial
efficacy. In this aim, it can be concluded that the combination of GS release and a PEG
surface coat can simultaneously kill and prevent infection while providing a non-adhesive
surface upon removal from the wound.
Polyurethane (PU) foam was characterized in a two-factor analysis based on foam
density and mixing speed used to create the foam layer. PU foam V was chosen as the
absorptive layer of the dressing and a comparative analysis was conducted using
commercialized absorptive dressings. The PU foam layer was exposed to different time
durations of ultra-violet ozone to increase the surface wettability and initiate moisture
absorption. To prevent saturation, PLLA yarn of 4DG fibers was braided into an
evaporative and moisture wicking layer. The braided fabric was able to vertically wick
porcine serum at a rate of 0.88 mm/sec. The combination of absorptive and moisture
wicking layers stimulate wound healing by removing moisture from the ulcer, while
preventing maceration and premature saturation of the dressing, leading to fewer dressing
changes.
Additionally, an in vitro chronic wound model was constructed to verify the
efficacy of the combined layers of the dressing. After applying the dressing for a duration
of 48 hours, the dressing inhibited bacterial infection, while acting as a superabsorbent
material without causing saturation. Further work explored healthy cell viability and any
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oxidative stress levels after exposing cells to both bacterial infection and the dressing.
Although the in vitro model maintains some limitations and assumptions at the present
time, it can be concluded that with the addition of the wound dressing, cell viability
increased over time, and therefore promoted tissue repair. Future work will explore
alternative antimicrobials for a more gradual release as well as improving the in vitro model
by discovering the interaction between the co-culture in different types of medias and
substrates while including proinflammatory biomarkers that could affect oxidative stress.
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PREFACE
There are approximately 441 million patients worldwide suffering from diabetic
chronic wounds, each accompanied by a high rate for hospitalization, amputation, and even
death. There are growing concerns related to the strategy for treating diabetic chronic
wounds such as the significant increase (54%) in the total population of diagnosed and
undiagnosed Diabetes Mellitus, the lack of awareness of ulceration due to comorbidities
such as neuropathy and loss of sensation, and finally, the extreme economic burden ($200
billion/year) placed on healthcare expense. Currently, there exists a T.I.M.E principle
(tissue debridement, infection and inflammation management, moisture control, and edge
effect) in which physicians rely on to help stimulate successful wound healing. However,
there are many assumed gaps in this strategy as the hospital readmission and reoccurrence
rate can reach as high as 20% and 50%, respectively. Therefore, researchers and clinicians
are investigating new holistic strategies to best influence all variables within successful
diabetic chronic wound healing.
This work demonstrates the design, development, and in vitro evaluation of a
multicomponent medical textile and absorptive wound dressing for the growing need to
initiate proper healing of chronic wounds. This holistic approach includes infection
management using optimal antibiotic uptake and release, moisture absorption and wicking
for the prevention of maceration, and non-adhesion for the prevention of unnecessary
autolytic debridement during dressing changes. Material type, fiber geometry, and drug
loading was manipulated to create an ideal antibiotic release for infection management.
Moisture absorption was optimized through the combination of foam and moisture wicking
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geometry. Non-adhesion was addressed through surface treatment of the skin-contact layer.
Additionally, the efficacy of this dressing was evaluated using a novel in vitro chronic
wound model that included a co-culture of fibroblast cells and bacteria in addition to a
microtubing system that supplied the model with porcine serum to mimic wound exudate.
The multicomponent wound dressing showed bacterial inhibition, while initiating
absorption without causing saturation, in addition to promoting cell growth for wound
repair. The ability to predict wound healing response from all dressing components
required for successful healing in vitro will help direct future in vivo studies by controlling
variables and preventing premature animal and clinical trials, ultimately reducing waste
and research cost.
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CHAPTER ONE
INTRODUCTION
Clinical Relevance
Given their severity and non-healing nature, diabetic chronic wounds are a growing
concern to the 30.3 million Americans diagnosed with diabetes mellitus (DM)1. Between
the years of 2015 and 2030, the total population of diagnosed and undiagnosed DM in the
United States will rise by 54%2. This growth can be due to a combination of factors such
as lifestyle, the aging population living longer, and the dramatic increase in Type 2 diabetes
in children and adolescents. Figure 1.1 depicts the rapid spread in prevalence of diabetes
and the correlation in geographic region.

Figure 1.1: Prevalence of diabetes in the US indicated by color and region between the
years of 2004 and 2016.1 (https://www.cdc.gov/diabetes/pdfs/data/statistics/nationaldiabetes-statistics-report.pdf)
The exponential increase in DM diagnoses overtime positively correlates to a
significant growth in diabetic chronic wounds, ultimately impacting the quality of life for
these patients as well as causing an extreme economic burden on current healthcare cost.
Although medication and advances in treatment have proven successful in preventing high
risk for death caused by diabetes and its comorbidities, the annual number of deaths caused
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by DM will rise by over 100,000 and contribute $200 billion to the total annual healthcare
cost2. Additionally, the chronic comorbidities associated with DM rise as the aging
population is living longer, placing an imperative need for improved prevention and
treatment.
One of the more common comorbidities of diabetes is hypertension. 75% of patients
with diabetes have concomitant hypertension, which can lead to many micro- and
macrovascular disorders3. Macrovascular complications can lead to coronary artery
disease, myocardial infarction, stroke, congestive heart failure, and peripheral vascular
disease. Microvascular conditions can lead to nephropathy and neuropathy3. Peripheral
neuropathy is one of the most frequent precursors of diabetic ulceration and occurs when
the peripheral nerves in the limbs become damaged4. A combination of reduced sensation,
poor blood circulation, and impaired healing ultimately leads to the formation of an ulcer.
Patients who suffer from diabetes have a 25% chance of developing a severe
chronic wound, more commonly referred to as a diabetic foot ulcer (DFU) contributing to
a global prevalence of 6.3%5,6. Those affected with DFUs and other chronic wounds are at
risk for severe infection, osteomyelitis, and amputation due to the lack of sensation and
awareness of the ulcer. If unrecognized due to the lack of sensation and awareness from
being on the plantar portion of the foot, a patient is at high risk for sepsis and death.
Currently, treatment is only as good as a patient’s willingness to comply to physician
instructions. Even when an ulcer is spotted and diagnosed early on and treatment
progresses, the incidence of new ulcer formation at a collateral wound site may be up to
50%, further spiraling into the chronic nature of DM and its comorbidities7.
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Pathophysiology
Diabetes mellitus is a disease in which the body’s ability to metabolize glucose, or
more commonly known as sugar, is impaired due to insulin deficiency. To accommodate
for high levels of unprocessed glucose, the pancreas becomes overburdened and tries to
make more insulin to store in cells8. Because glucose levels are rising at faster rates than
insulin can be produced, the glucose is forced to build up in the bloodstream, which can
cause detrimental effects throughout the body. The longer and less controlled blood sugar
levels become, the higher the risk for complications, such as coronary artery disease,
atherosclerosis, and stroke. Excess sugar can line the walls of vessels, capillaries, and
glomeruli around nerves causing retinopathy, neuropathy, and nephropathy leading to loss
of vision, numbness in the limbs, and end stage kidney failure8. Most significantly, nerve
damage and poor blood flow around the feet can lead to foot pain, change in gait mechanics,
and loss of balance. The foot can be susceptible to cuts, blisters, and calluses which can
develop serious infection, forming ulcers as seen in Figure 1.2. The lack of sufficient blood
flow to these ulcers contribute to poor healing and may require foot or leg amputation
depending on the severity of infection.
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Figure 1.2: Schematic of common locations that a DFU is likely to occur
(https://www.associatedpodiatristspc.com/blog/dealing-with-diabetic-foot-ulcers)
The complete pathophysiology of ulceration is still unclear; however, clinicians and
wound care specialists widely assert that delayed healing is due to complications of
peripheral arterial diseases, neuropathy, inflammation, and ischemia9. A combination of
impaired growth factor production, angiogenic response, collagen accumulation, fibrosis,
and abnormal pressure may result in ulceration and chronic cracks in the feet. Ultimately,
the wound healing response at the ulceration site can be characterized by symptoms of a
frustrated and prolonged inflammatory response.
Inflammation becomes activated within a day of ulcer formation and can last up to
two weeks or longer. Figure 1.3 illustrates the cellular response to tissue injury causing
many common symptoms as a result. Inflammatory cells, such as neutrophils,
macrophages, T-lymphocytes, fibroblasts, and prostaglandin E2 (PGE2) secrete enzymes
that result in pain, redness, warmth, tenderness and swelling necessary for the healing
cascade10,11.
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Figure 1.3: Inflammatory response leading to the 5 most common symptoms.
(https://ib.bioninja.com.au/standard-level/topic-6-human-physiology/63-defence-againstinfectio/inflammation.html)
Neutrophils activate upon responding to chemotactic signals that allow for cell
localization in the infected area. In a process called margination, neutrophils roll about the
vasculature and migrate into the wound site with the help of cell adhesion molecules
(CAMs) through diapedesis11. The lack of functional adhesion molecules at this point in
the inflammatory response delays healing11. Neutrophils release elastase and collagenase
for the purpose of destroying and removing damaged structural proteins. They also produce
tumor necrosis factor alpha (TNF-α) and interleukins 1 (IL-1), to allow for fibroblast and
epithelial cell homing11.
Macrophages are the second key inflammatory cells needed for phagocytosis and
releasing cytokines and growth factors, such as platelet derived growth factors (PDGF),
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transforming growth factors beta (TGF-β), beta fibroblast growth factors (β-FGF), TNF-α,
IL-1, and IL-6 for promoting fibroblast proliferation and reepithelialization. Finally,
lymphocytes, enter the wound and produce IL-2, needed to aid in fibroblast recruitment11.
The role of fibroblasts in the healing process is significant because they produce
matrix metalloproteinases (MMPs), which destroy impaired structural proteins. They also
release proteins that provide structural support for the new extracellular matrix11. In chronic
wounds, fibroblasts are non-receptive to cytokines and growth factors; as a result, their
activity is impaired, and there remains a distorted extracellular matrix11. Figure 1.4
illustrates the difference between acute and chronic inflammation. Fibroblasts release
tissue inhibitor metalloproteinases (TIMPs) in order to regulate the effects of MMPs.
Unregulated MMPs are overwhelming and destroy the old ECM in addition to fresh
structural proteins11.
Prostaglandin E2 (PGE2) is a hormone that is produced by blood vessels and
promotes vasodilation and angiogenesis by inducing vascular endothelial growth factors
(VEGFs). Thus, PGE2 is a vasodilator needed to prevent hypoxia. Individuals with DFUs
suffer from vascular disease and peripheral arterial disease due to lower levels of PGE211.
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Figure 1.4: Pathophysiology of healing and non-healing wounds12.
(https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6696601/)
Primarily, ulcers occur through minor trauma in the presence of sensory
neuropathy. Often, neuropathy is undiagnosed until ulcer formation or pain develops.
Diabetes is associated with nerve damage, which results from diseased vasa nervorum and
interacting metabolic abnormalities13. Hyperglycemia may inhibit the production of nitric
oxide, ultimately creating an environment that is more susceptible to reactive oxygen
species, such as superoxide and hydrogen peroxide. This can disrupt the productivity of
endothelium-derived vasodilator and can lead to a cascade of platelet aggregation,
inflammation, thrombosis formation, and atherosclerosis of small vessels neighboring
peripheral nerves, eventually leading to peripheral neuropathy. Although damage from
neuropathy is irreversible, controlling blood glucose levels can prevent further ulceration.
Other behavioral changes such as monitoring hyperglycemia, hypertension, smoking,
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cholesterol levels, and heavy alcohol use can prevent injury while promoting a better
healing environment.
Patients with diabetes may also have vascular disease and ischemia, which can
contribute to delayed healing. In fact, ischemia is a major contributor in 90% of DFU
patients who undergo amputation14. Therefore, there is a high correlation between ischemia
and atherosclerosis and highly infected DFUs. Capillary thickening can both interfere with
normal flow of inflammatory cells and create inelasticity, ultimately making it difficult for
vasodilation needed for responding to local injury15.
Because DFUs are chronic, treating infection can be challenging. Once an ulcer
forms, infection can build and spread due to open air wounds, lack of sterility and a loss of
innate barrier function14. Dysfunctional leukocytes are common among the inflammatory
response of patients with diabetes15. Additionally, phagocytosis is reduced due to
hyperglycemia, fibroblast migration is hindered, and the protective barrier and repair
mechanism slows down. Normal wound exudate levels are optimized for healing, while in
chronic wounds, exudate levels contain higher concentrations of MMP11. MMP-2 and
MMP-9 protein concentrations were 10 times and 25 times higher in pressure ulcer fluids
than surgical fluids, respectively16. The majority of pathogens found in DFUs are
Staphylococcus aureus, Enterococcus faecalis, Pseudomonas aeruginosa, and anaerobic
bacteria5. Pathogen concentration levels above or equal to 105 Colony Forming Units
(CFU) per gram are capable of interfering with the wound healing process5. Bacteria
proliferate towards this critical concentration level, and a biofilm forms as bacteria encase
themselves within extracellular matrix substances of polysaccharides and lipids. Resistance
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to immunological responses becomes a significant problem for patients with infected
chronic wounds.
Current Treatments and Challenges
There are four different depth ischemic classifications that can be used to diagnose
a DFU, as seen in Table 1.1 It is up to the clinician’s judgement to best classify these
wounds. Ultimately, the treatment plan falls on clinician subjectivity and experience.

Grade 0
Grade 1
Grade 2
Grade 3

Grade 4

Grade 5
References

Table 1.1: Major DFU Classification Methods
Wagner-Meggitt University of Texas
PEDIS
Pain only, no open
Pre-ulceration
ulcer
Superficial ulcer
Superficial wound
Skin intact, no infection or
loss of sensation
Deep ulcer
Wound penetrating
Superficial ulcer with
to tendon or capsule infection at the surface and
loss of sensation
Deep ulceration
Wound penetrating
Ulcer reaching the fascia,
with osteomyelitis
to bone or joint
muscle, and tendon;
fasciitis and septic arthritis
likely
Localized gangrene
Ulcer depth reaching the
bone or joint; systemic
inflammatory response
syndrome
Extensive gangrene
[14, 17, 18]
[19]
[20]

Once the ulcer is properly classified, a treatment plan can take place. Physicians
rely on evaluation that is based on the T.I.M.E principle. In correct order, the physician
must debride and necrotic tissue or callus formation, manage inflammation and infection,
alleviate any overwhelming moisture levels, followed by trimming the edge of the wound
to promote reepitheliaization.
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The first step in treatment is debriding the ulcer from any necrotic tissue and callus
formation. If infection is present, priority is placed on stopping the progression in order to
prevent the threat of osteomyelitis leading to amputation. Antibiotics can be used to treat
infection, but must be chosen based on the spectrum of bacteria present. Infections typically
contain a combination of S. aureus, Escherichia coli, and P. aeruginosa, which can be
killed by applying aminopenicillin and penicillinase inhibitor as well as quinolone,
metronidazole, and clindamycin20-22. Intravenous options of imipenem, gentamicin,
vancomycin, teicoplanin, rifampicin, or lenozoid can also be effective. Antibiotics place
limitations on treating infection as many pathogens can become resistant, especially during
biofilm formation. Many dressings commonly use hard metal nanoparticles, such as silver,
zinc, copper, and arsenic. These antimicrobial metals must be carefully monitored for the
development of toxicity23,24.
Wound Dressings
After infection is properly controlled for, the clinician can prescribe dressings for
the purpose of providing a barrier to the external environment as well as for the promotion
of healing. Currently, there are a wide variety of commercially available wound dressings
that have proven to enhance healing. Since treatment strategies depend on a unique
combination of comfort, promotion of reepithelialization, prevention of further trauma,
moisture, exudate wicking, antimicrobial properties, etc., the variance of these dressings
are extreme.
Wound contact materials are placed over the wound in the evidence of minor
exudation. Non-medicated dressings include paraffin gauze, while medicated include
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Xeroform® (Cardinal Health, Dublin, Ireland)25. Hydrogel, foam, and other absorbent
dressings are primarily used when managing highly exudated wounds. However, hydrogels
can also rehydrate a wound if moisture levels are too low. Common absorbent dressings
include Primapore® (Smith & Nephew, London/Hull, UK), Mepore® (Mölnlycke,
Gothenburg, Sweden) absorbent cotton gauze (BP 1988), OptiLockTM (Medline Industries,
Inc. Northfield, IL), and Cutimed® Sorbact® (BSN Medical, Hamburg, Germany)26-29.
Hydrogel dressings include ActiformCool® (Activa, Needwood, UK) and
Aquaflo® (Covidien, Dublin, Ireland)30-32. Algicell Ag (Integra

LifeSciences Corp.

Plainsboro, NJ) is similar to many hydrogel dressings. It is an alginate that is very
hydrophilic and forms a gel-like substance once hydrated33. Promgran Prisma®
(Systagenix, Quincy, MA) and DermaCol/AgTM (DermaRite Industries, North Bergen, NJ,
USA) are two collagen matrix dressings that can transform into a biodegradable gel if
exudate levels remain high within the wound34-36. Aquacel Hydrofiber® (ConvaTec,
Reading, UK) creates a soft gel-like material as it absorbs wound fluid, while maintaining
a moist environment37. Mepilex® Ag (Mölnlych Health Care, Gothenburg, Sweden) is a
vapor-permeable, waterproof film that regulates wound moisture while protecting the
environment from bacterial invasion38. TegadermTM (3M Health Care, St. Paul, MN) is
another popular dressing that not only absorbs exudate but is comfortable and easy to
remove from fragile and sensitive tissue36, 39. Figure 1.5 depicts a few common super-
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absorbent

dressings

necessary

for

managing

overwhelming

exudate

levels.

Figure 1.5: (A) Cutimed® Sorbact®, (B) TegadermTM, and (C) Mepilex® Ag as examples
of hydrogel and polyurethane type dressings, some of which contain antimicrobials29,38,39.
Film dressings are important to consider when a membrane layer is needed to allow
for the passage of oxygen and vapor, while preventing the invasion of water, exudate, or
bacteria32. Many polyurethane materials can be used for this purpose. One such example is
SentryTM (Acute Care Solutions, LLC, Canton, OH, USA), which provides a breathable
film that rids the wound of water, dirt, and microbes, while prohibiting leakage40. Similarly,
Silverlon® (Argentum Medical, LLC, Geneva, IL, USA) permits the passage of exudate,
while preventing microbial invasion and contamination36,41.
As mentioned before, silver has been used frequently to treat infected wounds.
ALLEVYN (Smith & Nephew, London/Hull, UK) is a polyurethane film combined with
foam containing silver sulphadiazine42,43. The release of antibacterial action was observed
to last up to approximately 7 days. DermaCol/AgTM (DermaRite Industries, North Bergen,
NJ, USA) is a collagen matrix wound dressing that contains silver chloride in order to
prevent bacterial colonization35. Many of the foam or hydrogel dressings such as Promgran
Prisma® (Systagenix, Skipton, UK), Mepilex® Ag (Mölnlycke Health Care, Gothenburg,
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Sweden), and Aquacel Hydrofiber® (ConvaTec, Reading, UK) contain silver within their
matrix to provide a protective barrier for not only fighting infection but also allowing for
an optimal healing environment34,36-38. Table 1.2 lists several common commercialized
wound dressings and their advantages and disadvantages when used to treat chronic ulcers.
Table 1.2 Common commercialized dressings used to treat chronic wounds
Name
Xeroform®

Company
Cardinal Health,
Inc.

Type
Absorbent
gauze

Advantages
1. Affordable
2. Comfortable

Primapore®

Smith&Nephew

Absorbent
adhesive
woven pad

1.
2.
3.

Low adherent
Breathable
Absorbent

Mepore®

Mölnlycke®

Absorbent
fabric

1.
2.

Low adherent
Comfortable

OptiLockTM

Medline
Industries, Inc.

Absorbent
polymer core
dressing

1.

Provides an
optimal moist
wound bed
Protects from
maceration
Non-adherent
Cleans
infected
wounds
Avoids
bacteria
resistance

2.
Cutimed®
Sorbac®

BSNMedical
Inc.

Bacteriabinding
dressing

3.
1.
2.

ActiFormCool®

Activa
Healthcare

Ionic hydrogel

1.

2.
Aquaflo®

Covidien

Hydrogel
transparent
dressing

1.
2.
3.
4.

Algicell® Ag

Integra
LifeSciences
Corp.

Antimicrobial
alginate
dressing

1.
2.

Promgran
PrismaTM

3MTM

Antimicrobial
collagencellulose
dressing

1.
2.
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Disadvantages
1. Not
antimicrobial
2. Saturates
easily
1. Not
antimicrobial
2. Susceptible
to autolytic
debridement
1. Not
antimicrobial
2. Saturates
easily
1. Not
antimicrobial
2. Locks in
exudate
1.
2.
3.

Donate or
absorb fluid
to maintain
optimal
moisture
Manages
wound pain
Absorbent
Translucent
Disk shape
Cooling
sensation
Antimicrobial
High
absorption

1.

Antimicrobial
Promotes
granulation

1.

2.
3.
1.

1.

References
25

26

27

28

No
antibiotics
included
Saturates
easily
Can cause
maceration
Not
antimicrobial
Not for upper
grade ulcers
Causes
autolytic
debridement
Maintains
moisture and
can cause
maceration

29

Not intended
for high
grade ulcers
or those with
Ag sensitivity
Delicate and
degrading
matrix

33

30

31

34, 36

tissue
formation
Antibiofilm
Removes
exudate

2.

Aquacel®
Hydrofiber®

ConvaTec

Antimicrobial
hydrofiber

1.
2.

1.

Mepilex® Ag

Mölnlycke®

Antimicrobial
foam dressing

1.
2.
3.

Absorbent
Antimicrobial
Adherent

1.

TegadermTM

3MTM

Transparent
film dressing

1.
2.

Waterproof
Transparent

1.

Silverlon®

Argentum
Medical, LLC

Absorbent pad

1.
2.

Antimicrobial
Absorbent

2.
1.

2.
ALLEVYN

Smith&Nephew

Absorbent
foam dressing

1.
2.
3.

DermaCol/AgTM

DermaRite®

Collagen
matrix
dressing with
Ag

1.
2.
3.

Absorbent
Gentle
adhesive
Can include
Ag as
antimicrobial
Promotes
granulation
tissue repair
MMP
inhibition
Absorbent

1.
2.

1.
2.

Nonabsorbent
Locks in
bacteria,
debris, and
exudate
Not intended
for highly
exudated
wounds
Nonantimicrobial
Adhesive
Not intended
for high
grade ulcers
or those with
Ag sensitivity
Saturates
easily
Can cause
maceration
Locks in
exudate
Delicate and
degrading
matrix
Locks in
exudate

36, 37

36, 38

36, 39
36, 41

42, 43

35, 36

Offloading Devices
After applying dressings, some patients require casting or other orthotics for
offloading purposes. Offloading has its uses in interrupting the pathogenic chain that
produces the ulceration, while shifting the histology of the ulcer from a chronic
inflammatory state to a condition suitable to healing44. Total contact casts (TCC) are a
contact cast system that is used to relieve pressure from areas of the foot that are prone to
ulceration45. Complete patient compliance and a degree of mobility make TCCs attractive
to most physicians, however the application takes skill and is labor intensive46. If not
applied properly, TCCs can cause skin abrasions or iatrogenic ulceration. They also are
frowned upon when treating infected DFUs47.
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Alternatives to TCCs include Charcot restraint orthotic walker (CROW), a
controlled ankle motion (CAM) walker, ankle foot orthoses (AFO), and wedge shoes, all
of which are depicted in Figure 1.6. Unlike the TCC, these are removable to control edema,
but also are less effective because the patient may not be compliant to wearing the brace
all the time. Also, a patient’s balance is interrupted as many of these orthoses are bulky
and not conducive to everyday wear48. Figure 1.6 depicts the six different offloading
devices to relieve pressure that disrupts wound healing or causes further ulceration.

Figure 1.6: Different orthotic options to offload pressure49.
(https://pubmed.ncbi.nlm.nih.gov/25514266/)
Shoes and insoles can be worn by patients with healed ulcers to transition to
pressures and shear forces of weightbearing. These shoes have insoles with removable
diamond or hexagonal shaped pieces to personalize the particular area of offloading48.
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Amputation
For those patients with significant threat of systemic infection, amputation is the
only known option to prevent further complication and death50. As of 2018 it was reported
that after every 30 seconds, there exists one lower limb amputation out of the global
diabetic population. Of that population, 85% are contributed by foot ulceration
catastrophizing the chronic nature associated with diabetes51. Cost associated with lower
limb amputation ranged from $16,488 to $66,215 (1998 currency)52. Much of what
contributed to the cost was not so much the surgery, but that of the rehabilitation medicine,
nursing home assistance, and internal medicine. Preventing amputation can substantially
alleviate the burden on public health, and ultimately improve the quality of life associated
with a loss of limb.
Research in Wound Dressings
The ideal wound dressing requires the combination of providing a barrier between
the ulcer and external environment and promoting healing. It must consider a material that
has the potential to be antimicrobial, maintain a moist environment, permeable to oxygen,
remove wound exudate, and allow the release of necessary growth factors in order for the
wound to facilitate proper proliferation and tissue repair and remodeling53. Both natural
and synthetic materials and their combination give rise to healing in their own ways.
However, labor, cost, and ease of use must also be considered to reproduce the optimal
dressing. Thus far, no single dressing has met all the needs for proper wound healing, and
therefore, further research is needed to explore a unique combination. The following
section focuses on recent progress in textile, foam, hydrogel, and organic wound dressings,

16

clinical outcomes, and the need to improve micro- and macro-scale geometry and overall
architecture.
Textile Dressings
Textile-based dressings include fibers, filaments, yarns, and woven, knitted, and
nonwoven materials. Fibers can be grouped into natural and synthetic categories. Natural
materials are typically cotton, cellulose, chitosan, silk, and linen, while synthetic materials
are polyester, polyamide, polypropylene, polytetrafluorethylene, etc54. Textile-based
dressings provide strength and precise control of degrading and drug releasing behaviors
if loading antibiotics or tissue growth factors for infection management and promoting
reepithelialization.
Choosing the right polymer is based on the fiber integrity and degradation rate
needed for the type of healing. Many polyesters, such as poly-lactide (PLA), poly(lactideco-glycolide) (PLGA), polycaprolactone (PCL), and their composites can be processed into
fibers of various type. PLGA offers tunable degradation rates when varying the ratio
between its monomers55. It has suboptimal mechanical properties for load-bearing
purposes, however. On the other hand, one of PLGA’s homopolymers, PLA, is much
stronger. It degrades much slower and absorbs less water due to its relative hydrophobicity
from the presence of an additional methyl group55. PLA’s hydrophobic nature may make a
suitable non-adhesive, skin-contact layer. PCL also has a slower degradation rate,
warranting use as a potential wound dressing. It has excellent water retention capacities
that capture wound exudate56.
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All polymers can be melt spun into fibers of varying sizes; however, very few can
possess versatility in cross-sectional shape due to vulnerability of absorbing moisture
quickly, thus altering thermal properties needed for extrusion as noted in previous research.
Additionally, the mechanical integrity of a monofilament or multi-fiber yarn must be
conducive for weaving or knitting. Knitted fabrics can provide good wrinkle and crush
resistance, higher elongation, and elastic recovery and permeability, allowing for tissue
ingrowth57. Wang et al. created a PLGA knit incorporated with collagen-chitosan
composition to measure the geometry’s role in tissue regeneration (Figure 1.7). The knit
provided mechanical strength in order to promote neotissue formation and blood vessel
ingrowth57. Nanofibers created via electrospinning can create continuous fibers, which
possess a similar architecture to the structure of the ECM. Additionally, porous features of
these electrospun fibers allows high surface-to-volume ratio needed for optimal cell
attachment and oxygen and nutrient transport58. Yang et al. developed electrospun fibrous
mats allowing for gaseous and fluid exchanges, while absorbing excess exudate and wound
debris. The electrospun fibers incorporated bFGF which resulted in enhanced collagen
deposition and ECM, similar to that of normal tissue58. Finally, woven fabrics can be used
where mechanical strength is required due to their elongation, high breaking strength, and
mechanical stability. There is a lack of emphasis on woven meshes for wound dressings;
however, this unique design is fast growing in areas of tissue engineering, such as hernia
and vaginal meshes as well as scaffolding for bone and cartilage regeneration59-61.
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Figure 1.7: Dermal substitutes made up of (A) PLGA yarn, (B) Collagen-chitosan, and
(C) Collagen-chitosan reinforced PLGA yarn57. Adopted with permission from Elsevier.
Foams
Foam-based dressings are a common approach to healing diabetic ulcers due to the
wide range of absorbency needed to control for the high amounts of exudate commonly
found in the ulcer bed. Foam-based materials are typically polyurethanes (PUs). PUs are
polymers that can be formed by combining polyols with isocyanates, and the link between
the OH (hydroxyl) and NCO of the isocyanate functional group results in the urethane
linkage. Because PUs are used as everyday life products, the evolution and research into
perfecting its manufacturing ease has made it cost effective. PU foam possesses advantages
of tunable softness, flexibility, breathability, and the ability to absorb moderate to high
levels of exudate. PU’s functions can be manipulated by altering the ratio of hard and soft
chains of the polymer as well as physical and chemical blowing agents, such as pentane,
hexane, and acetone and water to expand the polymer by CO2 produced62. It is also
important to consider compression that can withstand weight bearing activities as well as
contribute toward patient comfort. PUs contribute much to thermal insulation and comfort.
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They are easily cut to shape. Hydrofera Blue® READYTM (Hydrofera, Manchester, CT)
is one such example of a PU and Polyvinyl Alcohol (PVA) foam-based dressing as seen in
Figure 1.8 that incorporates methylene blue and gentian violet for bacterial prevention63.

Figure 1.8: Hydrofera Blue® READYTM composed primarily of PU foam.
Often, PUs are used as the absorbent material, sandwiched between a contact layer
and a waterproof film. Mepilex® Ag (Mölnlycke Health Care, Gothenburg, Sweden) is an
example of a tri-layered wound dressing, and it has shown effective healing for many types
of ulcers and burns64. Additionally, PU was electrospun to form a porous membrane that
could wick away fluid from the wound. Figure 1.5B depicts electrospun PU fibers and a
wound dressing prepared TegadermTM (3M Health Care, St. Paul, MN), made out of a thin
layer of PU and acrylic adhesives.
More uniquely, shape memory polyurethanes (SMPUs) are being incorporated into
composite materials to provide more ideal mechanical properties and stretching capabilities
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for personalized healing65. The material has shape memory function that can control
deformation and force, particularly in suture applications66. Tan et al., proposed to design
a composite nanofibrous mat that consisted of chitosan, gelatin, and SMPU through
electrospinning67. The gelatin and chitosan contributed to wound healing as the
incorporation obtained surface wettability, cytocompatibility, hemostatic properties, and
water vapor transmission. Whereas, the SMPU allowed for controllability upon tensile
force under different strains. In wound healing applications, the SMPU can eventually
assist in the closure of cracked wounds68.
Hydrogels and Hydrofibers®
Unlike foam-based dressings that control for wound moisture, both hydrogel- and
hydrofiber®-based dressings ensure that the wound remains moist with exudates without
causing maceration. Specifically, hydrogels are a water-insoluble, three-dimensional
network of polymer chains that are capable of absorbing large amounts of water69. They
can be molecularly tuned for specific biomedical applications, such as degradation rate, by
choosing many types of acrylic monomers and cross-linkers70. Hydrofibers® are based on
a novel technology that incorporates hydrocolloids and alginates to produce a fabric
composed of sodium carboxymethylcellulose. This product, similar to hydrogels, have a
unique gelling action, which allows the material to absorb and lock in wound exudate71.
Some natural and biocompatible hydrogels such as alginate and chitosan are found
in many wound dressings69. These dressings are specifically used for dry or dehydrated
wounds, partial or full-thickness lesions, abrasions or severe scrapes, burns, and radiation
skin damage. Many highly exudated wounds will not heal using hydrogel type dressings.

21

Algicell® Ag (Integra LifeSciences Corp., Plainsboro, NJ) (Figure 1.9A) is a calcium,
alginate-based wound dressings that is comprised of a mannuronic (high gelling) and
guluronic (high wet-strength) alginic acids33. The combination keeps the physical integrity
of the dressing. Aquacel® Ag EXTRA (ConvaTec, Reading, UK) (Figure 1.9B) is
composed of two layers of Hydrofiber® technology stitched together. It absorbs and retains
exudate directly into the vertical wicking fibers37.

Figure 1.9: Algicell® Ag and Aquacel® Ag EXTRA composed of alginic acids and
hydrofiber technology, respectively33,37.
Both Algicell® and Aquacel® dressings are beneficial in the sense that they reduce
pain while the dressing is in situ and upon dressing removal. Their components change in
formation upon absorbing wound fluid, creating a soft gel, while maintaining a moist
wound environment that aids in autolytic debridement33,37. Unlike Algicell®, Aquacel® can
encompass both wet and dry wounds. If the wound appears dry, a clinician can wet the
dressing with sterile saline over the wounded region. The vertical absorption properties of
the dressing will help to maintain the moist area over the wound. On the contrary, if highly

22

exudated, both dressings can cause maceration since there is a lack of moisture wicking
properties, making both hydrogel and hydrofiber® technology limited in ability.
Naturally-Occurring Materials
Natural materials are generally accepted in the world of wound care because of
their biocompatibility and environmentally safe applications, as well as their similarity to
the extracellular matrix (ECM). Therefore, natural-occurring materials are accepting of
biological systems and can prevent immunological reactions often in an already
immunocompromised state72.
Cellulose is the most abundant naturally-occurring material. Specifically bacterial
cellulose has excellent hydrophilicity, water-uptake capacity, permeability and tensile
strength. It has fibrous components similar to collagen. On the offside, cellulose lacks
antimicrobial activity, and therefore additional antimicrobial agents are required when
functioning as a wound dressing. Cellulose has been used in several wound healing
applications since it releases phosphodiesterase growth factor, epidermal growth factor
(EGF) and basic fibroblast growth factor (bFGF), all of which stimulate fibroblast growth
and anti-inflammatory effects73. Brassolatti et al., designed a bacterial cellulose dressing
on third degree burn wounds in rats and noticed optimized healing response74. Their results
indicated that the use of bacterial cellulose dressings with and without lidocaine had
comparable advanced repair outcomes, with both being more effective than the untreated
control group. Additionally, skin appendages, mild inflammatory cell influx, collagen fiber
organization and mild immunostaining were observed74.
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Next to cellulose, chitin is the second most abundant natural material and is
commonly found in arthropod exoskeletons or the cell walls of fungi and yeasts. Chitin can
produce chitosan via a thermochemical deacetylation process. Chitosan is a basic
antimicrobial homopolysaccharide and is naturally occurring in fungal cell walls. Chitosan
is a widely popular material for wound dressings due to its multifunctional properties such
as

nonantigenicity,

inertness,

nontoxicity,

biodegradability,

biocompatibility,

bioadhesiveness, antimicrobial properties, and hemostatic effects75-77. A chitosan based
Opticell dressing (Medline Industries, Chicago, IL, USA) (Figure 1.10) has hemostatic
efficacy. Stricker-Kongrad et al. examined the Opticell dressing on heparinized rats with
excisional wounds that mimicked debridement78. Researchers noted that after removing the
dressings, the total blood loss was significantly less than that of a typical gauze dressing.
This indicated that Opticell dressings with chitosan have hemostatic effects that could be
used to control bleeding associated with wound debridement78. Unlike cellulose, chitosan
has beneficial antimicrobial effects. When crossed with cellulose, the composite in the
form of film or hydrogel, inhibited the growth of E. coli and S. aureus, while enhancing
wound repair and epithelial regeneration in wound and burn infections79,80.
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Figure 1.10: Illustration of Opticell dressing placed over harvested donor skin.
(https://www.ciamedical.com/medline-msc9845ep-each-dressing-gel-fiber-opticell-ag4x5)
Another abundant natural polymer found in the ECM is collagen. Collagen is
present in most epithelial and connective tissues, such as bone, cartilage, ligaments, tendon,
and skin. It provides strength and integrity and is an essential component in cell-cell
interactions that regulate anchorage, migration, proliferation, differentiation, and
survival23,81,82. Collagen has been a key ingredient in promoting tissue granulation and
angiogenesis and in inhibiting bacterial growth in chronic wounds. Collagen has been used
as a carrier of reactive oxygen species, growth factors, and antibiotics. Wiegand et al.
fabricated a collagen and cellulose composite that demonstrated a reduction of cytokines
and proteolytic enzymes, indicating less inflammation in the wound bed83. A similar study
assessed the effect of collagen dressings on the size, granulation tissue, and bacterial
inhibition of chronic wounds. Patients with collagen-based dressings could avoid skin
grafting since the presence of granulation tissue was a suitable alternative. Additionally,
the dressing provided comfort, essential for patient compliance, as opposed to other
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conventional methods. Gelatin is a collagen derivative and is applicable to wounds that
need a more hydrogel-like material84. It is biocompatible and degradable in physiological
medium and can mimic many of the characteristics of the dermis. A research group that
used bFGF-impregnated gelatin microspheres found that gelatin stimulates angiogenesis
and fibroblast proliferation85.
Stimuli-Responsive Polymers
In recent decades, smart polymers have been heavily researched due to their
important characteristics pertaining to thermal, chemical, and physical responses needed
to modify the healing process. Unlike traditional synthetic or natural materials, smart
polymers can control material properties in response to external cues86. The following
studies highlight recent work in the analysis of smart wound dressings’ properties and the
mechanism used to create responses.
A stimulus-responsive hydrogel is a soft, hydrophilic material that swells upon the
absorption of water. They can be fabricated using copolymers, blends, or interpenetrating
networks (IPNs) and made to respond to various changes in their environment, such as pH,
temperature, chemicals, light, electric field, and shear stress87. Since pH values change
overtime in chronic wounds, a pH responsible hydrogel can swell or contract when exposed
to an overwhelming pH and ionic strength in the wound87. Additionally, mechanical
perturbations can be monitored by shear-responsive hydrogels. Hydrogels exhibit
viscoelastic mechanical behavior upon deformation and will strain in time-dependent
manner upon application of stress, such as loading and pressure beneath the ulcer bed. Once
an external stress is removed, the hydrogel can recover its original structure87.
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Dermal patches can be engineered by constructing a thermoresponsive drug
microcarrier encapsulated within a hydrogel layer. N-Isopopylacrylami (NIPAM) is a type
of thermoresponsive material commonly used as a drug vehicle. The hydrophilicity of the
material is dependent on temperature; it is hydrophilic below its critical temperature, 32°C,
and hydrophobic above. It can be tuned through copolymerization, allowing for optimal
drug release88. Bagherifard et al. designed a smart, hydrogel-based, dermal patch with
integrated heating elements for on-demand drug and growth factor delivery89. The patch,
as seen in Figure 1.11 included a calcium-alginate hydrogel sheet, micropatterned gold
heating elements, and the thermoresponsive NIPAM paticles89.

Figure 1.11: Schematic of a smart wound dressing depicting major elements89. Adopted
with permission from John Wiley and Sons.
In addition to proper conformability with the skin, the ability to maintain skin
moisture and protecting the wound from pathogens, the thermoresponsive drug carriers
within the chosen hydrogel controlled for drug release90.
As mentioned above, shape memory polymers (SMPs) are a form of smart polymers
that have the unique ability to remember its original shape upon stimulation65,91. Therefore
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it can fix a temporarily deformed shape, in this case an open cut or deep ulcer and to return
to its original shape. Polyurethanes are versatile SMPs due to many of its characteristics
listed above, such as tunable softness, porosity, and form (fiber, foam, etc.)91.
An ideal smart wound dressing can address personalized healing, while responding
to biological, chemical, and physical responses in the chronic wound environment. By
doing such, drug delivery, moisture absorption, wound contraction rate, and tissue repair
and remodeling can be controlled in response to environmental cues and ultimately, prevent
delayed healing.
Table 1.3 Comparison of different dressing types
Material type

Advantage
1.

Woven
polyester

2.
3.

Disadvantage

Fabricated into fibers of
various shapes and
yarns of different
patterns to stimulate
moisture movement
Fibrous structure is
similar to ECM
architecture
Resistant to many
solvents allowing for
slow and controlled
degradation

1.
2.

1.
1.

Foam

Hydrogel &
Hydrofiber®

2.

1.
2.
3.
1.

NaturallyOccurring
Polymers

2.

Semipermeable
membrane that prevents
bacteria from entering
Drainage properties that
decrease the risk of
swelling

2.
3.

Prevents maceration
Provides moist
environment for dry
wounds
Reduces pain

1.
2.
1.

Promotes tissue
granulation and
angiogenesis
Inhibits bacterial growth
and prolonged
inflammatory response

2.
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References

Must incorporate
antimicrobial
properties
FDA biomedical
approved materials can
be difficult to produce
continuous yarns of
different shapes

[84, 92-97]

Must be accompanied
by adhesives and
antimicrobials for
securement and
preventing infection
May cause maceration
Hydrophobic
properties that could
prevent moisture
uptake
Not intended for
highly exudated
wounds
Locks in moisture
Requires additional
antimicrobial
substances
Resorption in tissue
does not occur, which
could cause further
tissue damage or

[64, 93, 96]

[69]

[23, 81, 83, 84]

3.

1.

StimuliResponsive
Polymers

2.

Gelatin derivative
forming hydrogel
material

3.

1.

Personalized healing in
response to external
stimuli
On demand drug and
growth factor delivery
and shape memory
functionality

2.

become overwhelmed
by excess exudate
May require secondary
dressings
Sensing capabilities
could hinder
granulation tissue
repair
Not intended for
highly exudated
wounds

[66, 68, 86-91]

Fiber Geometry and Scaffold Architecture
In addition to material type, geometry and conformation of the wound dressing can
have just as big of an impact on successful healing. Important parameters to consider are
porosity, dimension, and strength of the graft as well as macrostructure to ensure orderly
extracellular matrix deposition97. Typically, one material does not fit all criteria. We
propose that a multilayered wound dressing is necessary to ensure all advantageous effects.
A porous, hydrophilic contact layer is needed to create a barrier between the outside
environment and wound, while promoting sterility and reepithelialization. A hydrogel or
nonstick material is best to prevent further damage to the granulated tissue. A second and
third layer is needed and relies on fibers oriented specifically to provide channels that can
wick away wound exudate both vertically and horizontally. Fiber cross-section is an
important variable to consider as it can alter capillary movement or fluid. In a previous
study, permeability and fluid wicking were tested as a function of weave configuration and
fiber geometry of various combinations of poly-l-lactide and poly-l-lactide-co-ecaprolactone. The outcomes suggested that grooved wicking geometry, as opposed to a
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round cross-section, may be used in scaffold development to regulate fluid transport toward
the area of interest97.
A second parameter to consider is a single or multi-filament architecture as a
component of the scaffold, especially for antibiotic delivery. A second experiment
investigated the elution profile of gentamicin in a bundle of small wicking fibers and a
single large fiber in order to test the effect of cross-sectional diameter on diffusion. The
burst release of the large single fiber was substantially greater than the bundle of fibers,
and the cumulative release was higher at each time point. Researchers concluded that the
bundle had a slower release profile due to a reduced surface area in contact with the buffer
solution when compared to the single large fiber. Although it has a slower release, the fiber
bundle exhibits a stable and consistent elution profile for a larger duration97.
Future Directions
This review of literature regarding the significance and prevalence of diabetic
chronic wounds, treatment, and current wound dressings indicates that future research
requires advancement towards a holistic approach to chronic wound healing in extreme
pathologic conditions, while also focusing on patient compliance, comfort, and cost. One
such area is to create a multicomponent, antimicrobial and superabsorber wound dressing
that controls for antibiotic release and reepithelialization and possesses a combination of
absorptive and wicking layers used to remove exudate while preventing saturation and
maceration. Antibiotic uptake and release will be monitored using three unique methods of
incorporation into the fabric. Promotion of granulation tissue repair from the skin-contact
layer will be analyzed via in vitro fibroblast growth and imaging to visualize non-adhesion.
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Absorption and wicking will be tested using both water and blood serum samples,
mimicking wound exudate viscosity.
Many dressings on the market focus on one or two areas but fail to recognize that
healing requires a simultaneous and combinational effect that encompasses managing
infection and controlling for moisture that can last for three days or higher. Ultimately this
can change the chronic nature of the wound and allow for epithelial tissue repair.
In parallel to the design and development of our multicomponent medical textile
wound dressing, a new approach to verify our product considers an in vitro wound model
that combines a co-culture of stressed fibroblast cells and rapidly growing pseudomonas
with a micro-vascular system that continually supplies blood serum to mimic wound
exudate. Due to the complexity of the substrates needed to create a model wound as well
as the frustrated inflammatory response associated with diabetes, there is limited research
and literature, making this final aim both novel and advanced. The in vitro wound model
will properly control for the dressing’s antibacterial, absorptive, and biocompatible
properties conducive for chronic wound healing. Not only will this approach provide
understanding for the development of in vitro wound healing assessment, it prevents
premature animal model testing while promoting Russell and Burch’s ethical framework
regarding the “Three R’s”, replacement, reduction, and refinement.
The combination of the multicomponent medical textile wound dressing and its
associated verification test will allow for further understanding in the complexity of
chronic wound healing, composed of multiple pieces (antimicrobials, moisture
management, non-adhesion, biocompatibility, etc.). Each of these factors work
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simultaneously to reduce the chronic nature of the wound, while promote healing, patient
and physician satisfaction, and reduced hospitalizations that contribute to overwhelming
healthcare costs.
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CHAPTER TWO
DESIGN AND DEVELOP AN ANTIBACTERIAL AND NON-ADHESIVE SKINCONTACT LAYER FOR INFECTION MANAGEMENT
Introduction
Diabetic chronic wounds are a growing concern to 6.3% of the global population.
Diabetic chronic wounds include foot, venous, and pressure ulcers, and are characterized
by a frustrated and extended healing process1. Comorbidities associated with diabetes
mellitus (DM) that may impede healing include peripheral arterial disease, neuropathy,
limited joint mobility, and abnormal foot pressures2. Early recognition and awareness are
imperative to successful healing; however, the loss of sensation as a result of peripheral
neuropathy can make it difficult for a patient to sense excessive pressure. Due to the high
risk for osteomyelitis and lower extremity amputation, early recognition, proper diagnoses,
and patient compliance are key for successful healing3.
Upon recognition and diagnoses, infection management is the first task of
treatment. Treating infection within a diabetic chronic wound may be challenging due to
open air wounds, lack of sterility, loss of innate barrier function, and unsanitary surfaces
that the plantar portion of the foot may contact4. Common pathogens found in many lower
extremity wounds are Staphylococcus aureus, Enterococcus faecalis, Pseudomonas
aeruginosa, and many anaerobic bacteria. Often the presence of a biofilm in which bacteria
proliferate towards a critical concentration level can become a significant problem when
treating infected chronic wounds5. If the ulcer contains necrotic tissue around the periphery
of the wounded area, often physicians will debride the wound. Ultimately, this may make
the surface area of the wound larger, but ideally, the process scrapes away unwanted
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pathogens so the wound is starting from a “clean slate” before planning alternative
treatment strategies (i.e. wound dressings, offloading devices, etc.). After debridement,
physicians may apply or administer antibiotics, either orally, topically, or within dressings.
Antibiotics must be chosen based on the spectrum of infecting organisms. S. aureus and
Escherichia coli typically make up common infections and can be treated by applying
aminopenicillin and penicillinase inhibitor or intravenously by using imipenem,
gentamicin, vancomycin, teicoplanin, rifampicin, or lenozoid6-8.
Wound dressings are commonly designed to provide both a barrier to any
contaminants in the air or surrounding environment and a warm, moist environment
required for healing9. There are many commercially available dressings that have shown
potential in healing diabetic chronic wounds; yet, the variance among them proves the lack
of a holistic approach that accomplishes the multiple factors necessary for healing2. The
appropriate material type and architecture of the dressing is important when controlling
releasing rates of antibiotics or growth factors. Medical textiles have indicated a promising
solution for chronic wound healing due to their versatility and modulation of dressing
parameters. Unlike natural materials, synthetic polymers used to fabricate dressings are
relatively insensitive to enzymatic and biological degradation allowing them to create a
stable environment for healing10. Many polyesters in various forms, not only provide
mechanical strength necessary for weight bearing dressings, but also can play a role in drug
delivery11-13. Synthetic materials can be shaped into fibers of different sizes and crosssections to best represent that of the extracellular matrix14. Medical textiles have the
advantage of controlling the porosity, dimension and strength of the graft as well as
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ensuring the microstructure of the new granulation tissue. Additionally, synthetic textiles
have been part of history for over two centuries allowing for a deep foundation of mass
production, allowing for possibilities in design for manufacturing15.
The skin contact layer is typically the layer that sits flush with the wound bed to
protect tissue from other layers of the dressing as well as other external stimuli. Contact
layers can be designed to conform to the shape of the wound and are often porous to allow
for the passage of moisture to a secondary absorptive dressing16. It is important that contact
layers consist of a breathable and non-adhesive material for promoting epithelial tissue
repair and remodeling while preventing debridement of the fragile granulation tissue upon
dressing changes. Because of the higher probability of contact with infected wounds, the
skin contact layer should also be antimicrobial. The unique design of the contact layer
requires a functional material that is conducive to antibiotic uptake and release while
preventing unnecessary autolytic debridement, all of which are necessary for early stages
of treatment.
Current Wound Dressings that Emphasize a Skin-Contact Layer
Currently there are a wide variety of commercially available dressings that include
skin contact layers that have proven to minimize some unnecessary autolytic debridement.
Because the skin contact layer is a relatively new idea, however, limitations arise such as
dislodgment and pain. Additionally, infection can worsen if the non-adhesive technology
is not antimicrobial.
Several of these contact layers are made of natural materials, while others contain
synthetic materials. ColActiveÒ (Covalon Technologies, Ltd. Mississauga, Canada) is
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composed of natural collagen and sodium alginate. Its porous and sterile sheet is absorbent
and stimulates wound healing17. Collagen can be a common allergen and therefore is not
suitable for all populations in the market. Unlike ColActiveÒ, CuticellÒ (BSN Medical
Inc., Charlotte, NC) and Conformant 2 Non-Adherent Contact Layer (Smith&Nephew, Inc.
London, UK) are made up of synthetic materials. CuticellÒ is a one sided silicone wound
contact layer with a perforated structure to allow for viscous exudate to pass through18.
Conformant 2 is composed of high density polyethylene. Both CuticellÒ and Conformant
2 provide transparency for continual visual inspection and monitoring of healing. There
has been some evidence that Conformant 2 can cause irritation, sensitivity, and maceration
in addition to unnecessary debridement, increasing the area of the wound after the first few
dressing changes19. Like that of CuticellÒ, MepitelÒ Wound Contact Layer (Molnlycke
Health Care, Sweden) is also composed of silicone. Its non-adhesive property has been
proven suitable for abrasions, wounds, and lacerations as it prevents the dressing from
sticking to the wound while reducing pain during dressing changes. Due to its geometry
and pressure sensitivity, imprints and infection can occur20. Uniquely, TegadermTM NonAdherent Contact Layer (3M, Saint Paul, MN) is made of woven, nylon fabric. It
minimizes disruption of granulation tissue and some patients have mentioned less pain
present upon removal21.
Currently contact layers typically emphasize non-adhesion, but the combination of
preventing disruption of granulation tissue while also preventing infection is necessary.
Therefore, future technology must incorporate antimicrobials within the skin contact layer
to better reach infected areas of the wound.
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Antibiotics
The most common antibiotics embedded in wound dressings are classified into four
categories: 1) quinolones, 2) tetracyclines, 3) aminoglycosides and 4) cephalosporins.
These antibiotics can work in one of four pathways: inhibition of bacterial cell wall
synthesis, blockage of key metabolic pathways, interference on protein synthesis, and
inhibition of nucleic acids synthesis, respectively22.
Quinolones, most commonly known as either amoxicillin or ciprofloxacin, inhibit
the bacterial DNA gyrase or the topoisomerase IV enzyme, ultimately preventing DNA
replication and transcription22,23. Both antibiotics can inhibit tested strains of E. coli and S.
aureus. Amoxicillin also treats Candida albicans and P. aeruginosa, and ciprofloxacin
can also treat some bacillus and subtilis strains24-28. Most quinolones can be administered
orally and intravenously. They have minor adverse effects, such as nausea, headache,
dizziness, and confusion. Inappropriate usage of them can cause resistance23.
Tetracyclines, also known as doxycycline, are bacteriostatic antibiotics that bind to
the 30S subunit of the ribosome, ultimately inhibiting bacterial protein synthesis29. They
can treat E. coli, S. aureus, and Streptococcus agalactiae30,31. Most tetracyclines are
administered orally. Some GI disturbances have been found. Also, photosensitivity and
bone and dental effects, such as staining of the teeth and abnormal bone growth can occur.
Additionally, tetracyclines can decrease the effectiveness of oral contraceptives, while
strengthening some oral anticoagulants29.
Aminoglycosides, known as gentamicin or kanamycin, are similar to tetracyclines
in that they inhibit protein synthesis29. Gentamicin treats the widest array of bacteria, such
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as E. coli, S. aureus, P. aeruginosa, Bacillus, and subtilis30,32. Kanamycin treats
specifically Listeria monocytogenes as well as P. aeruginosa33. Aminoglycosides are
poorly absorbed orally and are usually given intravenously. Some can cause renal toxicity
over large periods of time. Also, some gram negative bacilli and staphylococci are
resistant29.
Cephalosporins, known as cefuroxime and cefepime, are bactericidal beta-lactam
antibiotics that inhibit enzymes in the cell wall of bacteria, disrupting cell synthesis. They
mainly treat strains of E. coli and S. aureus34. Some adverse effects include
hypersensitivity, leukopenia, thrombocytopenia, and positive coombs test.
Methylene blue, iodine, and chlorhexidine are common antiseptics found in many
dressings, intravenous securement devices and adhesives, flushes and other surgical
instruments. Methylene blue is a dye that was first used to stain and inactivate certain
microbes. It can also be used to treat diseases and infections such as malaria,
methemoglobinemia, and urinary tract infections35. Recent technology has impregnated
methylene blue into DermaBlueTM and HydroferaBlueÒ absorptive wound dressings to
prevent microbial invasion36,37. It has minor toxic effects and the blue dye can perfuse
through skin causing some cosmetic issues. Povidone-iodine (PVP-I) is another antiseptic,
typically used as a disinfectant of the hands of healthcare workers as well as in preoperational surgical areas. There are some minor side effects associated with treatment
with PVP-I, such as skin irritation and swelling38. IoPlexÒ and DermaWoundÒ are two
types of wound dressings that incorporate PVP-I into their polymer matrix39,40. IoPlexÒ is
engineered with complex technology that controls the release for regulated and sustained
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levels of PVP-I. Uniquely, the color changes from black to white during the progression of
release indicating the time for dressing changes39. Finally, chlorhexidine , a bisbiguanide
compound known for bactericidal properties that inhibits growth throughout a 7 day
contact time, while exhibiting little to no adverse and cytotoxic effect41. TegadermTM CHG
(3M, St. Paul, MN, USA), BeneHoldTM CHG (Avery Dennison, Glendale, CA, USA), and
SurgiClearTM (Covalon Technologies, Mississauga, Canada) are adhesive dressings that
incorporate CHG in their matrix to protect the wounded areas42-44. All devices have been
shown to significantly reduce bioburden. SurgiClearTM has dual antimicrobial action, using
chlorhexidine and silver to provide protection throughout the entire surface area for up to
seven days. The combination can kill 99.99% of bacteria and yeast44. Chlorhexidine in
relatively high doses can cause skin irritation as well as oxidative stress to healthy human
cells.
Polyhexamethyl biguanide (PHMB) is a widely used antimicrobial used to kill
bacteria by entering host cells and binding to the bacterial chromosomes used in bacterial
replication45. It has been used in many cosmetics, personal care products, fabric softeners,
contact lens solution, hand washes, etc46. Relative to wound care, PHMB GEMCORE360
(GEMCO Medical, Hudson, OH), CurityÒ AMDTM (Cardinal Health, Dublin,OH), and
McKesson PHMB (McKesson Medical-Surgical Inc., Richmond, VA) have incorporated
PHMB as an antimicrobial that acts on a plethora of microbes such as MRSA, MRSE< VRE,
E. Coli, Klebsiella pneumoniae, P. aeruginosa, C. albicans and Rhodotorula mucilaginosa.
Health care providers must act with caution when using cleanser solutions around the
dressing, as the antimicrobial could be inactivated47-49. Recently, the Health & Safety
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Executive within the United Kingdom decided to place a ban on incorporating PHMB in
human hygiene products. There has been some evidence reported that exposure to high
levels of PHMB can cause cancerous side effects and gene mutations46. Therefore,
although a major element in destroying pathogens, further research must explore the
detrimental effects towards healthy systems.
In addition to synthetic antibiotics, metal nanoparticles (NPs) such as silver (Ag),
gold (Au) and zinc (Zn) also have been shown to have bacteriostatic and/or bactericidal
activity. They have recently shown promise in the world of wound care due to their lack of
severe side effects, while preventing microbial resistance50. When in contact with bacterial
cell walls, the attraction between negatively charged bacterial surfaces and positively
charged metal ions forms holes51. Metal NPs then affect metabolic pathways, disrupt
mitochondria, and interfere with protein synthesis through pH modifications52,53.
Ag NPs, often found in common dressings such as AquacelÒ Ag (ConvaTec,
Deeside, UK), AlgicellÒ Ag (Integra LifeSciences Corp., Boston, MA), and MepilexÒ Ag
Mölnlyche Health Care AB, Sweden), is a popular antimicrobial NP due to its extensive
inhibitory profile towards more than 650 microbe species and antibiotic resistant bacteria54.
Ag inhibits the bacterial reproduction by denaturing bacterial DNA, ultimately leading to
cell death. The bactericidal characteristics of AgNPs are dependent on particle shape, size,
and concentration55,56. Smaller AgNPs sizes not only increase biocompatibility but also the
effectiveness against S. aureus57. Unfortunately, Ag NPs can have the same negative effect
on healthy cells. The minimum inhibitory concentration of Ag needed to kill and prevent
all microbes found in the infection can be severely toxic to normal human cells58.
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Zinc is another metal nanoparticle active against some antibiotic resistant bacteria
and typically comes in the form of Zinc Oxide (ZnO)59,60. The mechanism for how it
interacts with bacteria is still unclear. Research has proposed a combination of the
destruction of cell integrity, ROS formation, and the release of antimicrobial ions. ZnO
NPs produce ROS that impede strains of E. coli and S. aureus biofilm development61-63. It
has been found that at proper concentrations, ZnO has antibacterial activity without
affecting normal cells64,65.
AuNPs are another more biocompatible antimicrobial agent, but must be delivered
by gelatin, chitosan, or collagen to be used in wound healing66-69. AuNPs penetrate
bacterial membranes and interrupt DNA transcription70,71. In doing so, the healing rate
increases, the inflammatory stage reduces, and collagen degradation builds, further
promoting reepithelialization72.
There is relatively little research regarding metal NPs and their long-term side
effects. Although metal NPs have shown potential in treating resistant bacteria and biofilm,
the adverse effects remain severe if concentrations and release of the NPs aren’t controlled
for. Specifically, AgNPs can accumulate within various organs, such as the brain, lungs,
spleen, kidney, and liver22. ZnO NPs can cause some toxic effects due to their enhancement
of oxidative stress in mammalian cell lines73,74.
An alternative approach to antimicrobials is using a physical barrier to ward off
unwanted pathogens. As mentioned in Ch. 1, CutimedÒ SorbactÒ (BSN Medical Inc.,
Charlotte, NC), features DACC technology, a bacteria-binding hydropolymer75. Similarly
BIOGUARDÒ Barrier (Integra LifeSciences Corp., Boston, MA) creates a physical
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antimicrobial barrier76. The benefit of physical barriers as an antimicrobial agent prevents
the possibly of antibiotic resistance or skin irritation from hypersensitivity. However, the
amount of bacteria that can bind to the barrier of the dressing is dependent on the surface
area and therefore, can lead to saturation and multiple dressing changes77.
Methods of Incorporation and Architecture of the Contact Layer
Engineering a wound dressing that incorporates antibiotic into the material remains
a challenge when effectively killing and further preventing infection. Currently, limitations
that reduce the efficacy in many drug delivering medical implants are the non-specificity
of the topical antibacterial therapies and the inability to properly detect bacterial
infection78. Many dressings loaded with the antibiotics described above have only
minimally addressed these challenges. The proper concentration of antibiotic and regulated
release profile is needed to prevent disrupting the cutaneous microbiome, antibiotic
resistance, and systemic toxicity79. Therefore, how the antibiotic is loaded and released,
which is dependent on geometry of the fiber, overall architecture of the fabric, and
methodology of incorporation, can greatly reduce these challenges.
Soaking
Soaking is a conventional method where the fabric is immersed in antibiotic
solution80. The uptake and release profile are dependent on the concentration of the
antibiotic solution as well as the time it takes to diffuse into the fabric. Additionally,
diffusion of the antibiotic molecule remains to be a challenge as most often antibiotics have
a large 3-dimensional shape that makes it difficult to embed themselves into the polymer
chains. Often, heat is used, typically around the glass transition temperature of the polymer,
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to loosen the polymer chains, making it easier for the complex antibiotic molecules to
diffuse into the fiber. A thermal analysis of the material of choice must be completed in
order to prevent recrystallization of the polymer. Typically, the solution forms a topcoat
over the fibers over time. This can cause an initial burst release effect. Antibiotic waste can
be a problem due to a portion of the solution not being loaded in the fibers80.
Dyeing
Dyeing is another value-added treatment for most textile materials. The dyeing
process is the interaction between a dye and a fiber and the movement of the dye into the
core of the fiber81. Unlike soaking, dyeing relies on two parts: adsorption or the transfer of
dyes from the aqueous solution into the fiber surface and diffusion, dyes embedded within
the fiber. Exhaustive dyeing is a specific type of dyeing process, where the fabric is loaded
into a bath, allowing it to come into equilibrium with a solution, or suspension, of dye81.
The extent of dyeing depends on temperature, time, specific liquor ratio, and the method
of agitation (machine) used. The goal of dyeing is to maintain antibiotic release over longer
periods of time, rather than a burst release effect. Figure 2.1 depicts of the process of dyeing
using a dye preparation, dyeing, and rinsing three-part technique.

Figure 2.1: Mechanism for exhaustive dyeing.

50

Solvent-based incorporation
Solvent casting and electrospinning to form homogenous drug loaded films or
nanofibers are useful for embedding the antibiotic within the material. A polymer and the
chosen antibiotic is dissolved in organic solvent, casted into a mold or set of non-woven
fibers and left to dry. Over time, the solvent evaporates, ultimately creating a film or fibrous
sheet of just the polymer and antibiotic. This can be an advantageous method because, like
dyeing, the antibiotic diffuses slowly overtime. There are some limitations, however. This
method limits the architecture to a thin film or nonwoven, irregular mesh of nanofibers.
Secondly, leaching of the drug can occur and is dependent on physiochemical and
biological properties of the polymer, antibiotic, and solvent, such as temperature, surface
area, microorganism activity, mineralogy, and crystal structure82. Lastly, most solvents
used to dissolve polymers, such as chloroform, toluene, acetone, and ethyl-acetate, can be
toxic to most organs if not entirely evaporated and overly exposed83.
Micro-scale geometry
Recent technology has allowed for the development of extruding fibers with unique
cross-sections for the purpose of moisture wicking, performance, comfort, bulkiness, and
tactility84. Some common shapes of fibers are round, scalloped oval, cruciform, lobular,
trilobal, square with voids, star-shaped, and hexachannel85. Clemson University holds the
ownership of a unique shaped fiber, called 4DG, or 4-deep grooved. The fiber shape was
developed by the Eastman Chemical Company (Kingsport, TN) and is unique because of
its eight microchannels created by the protrusions from the main fiber body, as seen in
Figure 2.284.
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Figure 2.2: Cross-section of 4DG monofilament. Adopted with permission from John
Wiley and Sons.
This shape was designed with deep grooves or channels along the longitudinal axis
of the fiber. The grooves provide channels that can serve as ducts to move fluid
spontaneously and provide large surface areas (up to 300 percent that of round fibers) for
a given denier per filament84. Another advantage of the 4DG shape is its relatively larger
surface area when compared to round fibers. Therefore, when incorporating antibiotic into
the fiber, the uptake of antibiotic should be larger, in theory, which could alter the release
profile and ultimately bactericidal response.
In this chapter, we first investigate the effect of antibiotic incorporation and
geometry of the individual fibers in a poly-l-lactide (PLLA) contact layer impregnated with
gentamicin sulfate (GS). GS was chosen as the antibiotic due to its robust nature that acts
on a wide range of gram negative and gram positive bacteria. It has been suitable in
preventing bacteria invasion in eye drops and topical ointments and creams. We then verify
biocompatibility on healthy cells. Non-adhesion properties were incorporated into the
contact layer by adding a thin surface layer of polyethylene glycol (PEG). The following
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discussion emphasizes how the combination of polyester medical textiles can address
versatility through material, macrostructure, and fiber cross-section to best optimize
antibacterial efficacy and non-adhesion for a novel skin-contact layer.
Research Objectives
Specific research objectives for this work included the following items:
1. Selecting a suitable biocompatible polymer for the baseline material of the skin
contact layer that is conducive to knitting
2. Determine the effect of antibiotic incorporation and geometry of the fibers on
antibiotic release and bacterial inhibition
3. Determine healthy fibroblast viability through metabolic activity assays
4. Modify the surface chemistry of the contact layer to promote non-specific cellular
adhesion
Materials and Methods
Extrusion Process
Poly-l-lactide (PLLA) (Jamplast, Ellisville, MO) was melt-spun into 36 filaments
of round or 4DG cross-sections using a quad component melt extruder (Hills Incorporated,
Melborne, FL). Differential scanning calorimetry (DSC) was used to obtain the glass
transition (Tg) and melting temperature (Tm) needed to derive the extruder’s four heating
zones. Final heating zones for PLLA were 185°C, 205°C, 220°C and 210°C. The fiber
diameter was controlled by the pump speed at the extruder outlet and the drawing rate of
the sequential rollers and spool used to collect the fiber post-extrusion. The fibers were
extruded at a 20 RPM pump motor speed resulting in 300 µm yarn.
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Three additional polymers, namely poly-l-lactide-co-glycologic acid (PLGA), poly
-e-caprolactone (PCL), and polyl-l-lactide-co-caprolactone (PLC) were chosen to compare
the ease of extrusion and knitting, relative to PLLA in a pilot study. It appeared that all
three additional polymers had difficulty extruding into shaped multifilament yarns due to
their sensitivity of moisture uptake prior to extrusion, thus altering their thermal properties.
Therefore, PLLA, being more versatile, robust in humid environments, and conducive to
knitting, was chosen as the material.
Pre-treatment and Knitting
Due to mechanical weakness, the PLLA yarn with filaments of 4DG cross-section
were pretreated to give strength to the yarn by adding 150 twists per meter (Agteks Direct
Twist machine – Model C10). The PLLA yarn was knitted using a 54 gauge, 220 needle
circular knitting machine (Lawson-Hemphill, Model FAK). Contact layers were cut into
round discs of 2 cm or 1.25 cm diameters for antibacterial analysis and biocompatibility
experiments, respectively.
Cleaning Process
Before antibacterial incorporation, each contact layer was cleaned and prepared for
bacteria or cell culture via the protocol outlined in Figure 2.3. Contact layers were washed
in 70% ethanol followed by a 5 minute drying period and rinsed in sterile deionized water
followed by a 30 minute drying period. Those contact layers used for biocompatibility
experiments also received a 15 minute soaking period in Dulbecco’s Modified Eagle
Medium (DMEM) (Atlanta Biologics, Flowery Branch, GA), fetal bovine serum (FBS)
(Life Technologies, Carlsbad, CA), and antibiotic-antimucotic (AA) (Life Technologies,
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Carlsbad, CA) with ultra-violet (UV) light exposure on each side of the contact layer.
Lastly, contact layers were dried for one hour.

Figure 2.3 : Contact layer cleaning process.
Antibiotic Incorporation
Three methods for incorporating GS into the contact layer were compared in this
study, as seen in Table 2.1. (1) The diffusion method was tested to determine the effects of
GS at the surface in addition to the potential initial burst effect of its release profile. Contact
layers were submerged in solutions of 0 µg/mL, 10 µg/mL, 100 µg/mL, 1,000 µg/mL, and
10,000 µg/mL of GS (Thermo ScientificTM, Waltham, MA) in deionized water, and
soaked overnight. (2) The heat-enabled diffusion method consisted of a similar soaking
treatment but also included a heat treatment, thought to soften the contact layers to allow
the PLLA fibers to incorporate GS deeper into the yarn. Contact layers were submerged
overnight in solutions of 0 µg/mL, 1 µg/mL, 10 µg/mL, and 100 µg/mL of GS. Prior to
submerging, the solutions were heated to 40°C to soften the yarn without causing
recrystallization of the polymer. For these two methods of incorporating GS, the contact
layers were then dried for one hour before exposure to bacteria or cell culture. (3) Thirdly,
the dyeing method was thought to embed the GS molecules deeper within the individual
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fibers of the yarn. Concentrations of 0 µg/mL, 1 µg/mL, 10 µg/mL, and 100 µg/mL of GS
were created and used as the dye solution. The fabric was dyed at a temperature of 60°C
for 120 mins before rinsed.
Table 2.1: Summary of GS Incorporation Methods
Diffusion Method
Description

Heat-enabled
Diffusion Method

Soaked contact layers
Soaked contact
in GS solutions (10,
layers in GS
100, 1,000, and
solutions (1, 10,
10,000 µg/mL) at
and 100 µg/mL) at
room temp overnight
40°C overnight

Dyeing Method
Fabric dyed in GS
solution dye (1,
10, and 100
µg/mL) at 60°C
for 120 mins

Round yarn

N=3

N=3

N=3

4DG yarn

N=3

N=3

N=0

Gentamicin Release Analysis
Contact layers were transferred to a 12-well plate containing 1.25 mL of PhosphateBuffered Saline (PBS) (Life Technologies Limited; Thermo Fisher, Grand Island, NY,
USA) and incubated at 37°C and 5% CO2. The well plate was then agitated on a shaker
plate while incubated to prevent reabsorption of the GS onto the yarn. GS loaded into the
yarn of the contact layer was then eluted into the 1X PBS over time. This procedure was
performed to determine the amount of GS elution over a period of 5 days. The PBS was
collected in 1.5 mL microcentrifuge tubes and stored at -20°C until the GS analysis was
performed. The wells were refilled with 1.25 mL of 1X PBS until the next time point. The
eluted samples were collected for short-term intervals (0, 1, 3, 6, and 9 hours) and longterm intervals (1-5 days).
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The amount of GS over 5 days was determined using a spectrophotometric
technique developed by Frutos and coworkers86. To quantify GS, equal proportions of
sample and fluorescent agent, o-pthaldialdehyde (OPA) (Sigma; St. Louis, MO) were
combined. The OPA reagent reacts with the primary amine functional groups on the GS
molecule forming a fluorescent detectable complex. A standard curve of known solutions
of GS was created (Table 2.2) to determine the relation between fluorescence and GS
concentration.
Table 2.2: Standard curve concentrations (µg/mL) for GS detection
Standard curve
concentrations

0

1

5

10 50 100 250

500

Each stored sample was thawed to room temperature and 100 µL of standard
concentration and sample were added to a well of a black-bottom 96 well plate (Corning;
Fisher Scientific, Waltham, MA, USA). 100 µL of OPA reagent was added to each well to
detect GS. The plate was read with a Synergy MX Multi-Mode Reader (BioTek; Winoosky,
VT, USA) at an excitation wavelength of 340 nm and an emission wavelength of 455 nm.
The standard curve was created using the fluorescent readings and a linear curve fit to
determine the regression between fluorescence and GS concentration. The unknown GS
from the eluted samples were calculated using the fit and their corresponding fluorescence.
Antibacterial Efficacy Testing
The contact layers of various GS concentration and method of incorporation were
tested to determine the antibiotic efficacy against Psuedomonas putida. P. putida is a gram-
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negative bacteria commonly found in soil and many other environmental niches that can
cause serious infection and outbreaks in humans87.
Liquid Broth Analysis
Using culture tubes, P. putida was inoculated in 4 mL of sterile Liquid Broth (LB),
Lennox (Fischer Scientific, Fair Lawn, NJ) and incubated at 37°C and 5% CO2 overnight.
Four culture tubes were made to generate enough cultured bacteria for each contact layer
treated with varying concentrations of GS. The culture tubes were set on an agitator plate
to prevent pellet formation while promoting homogenous mixture of P. putida in LB. After
resuspension of bacterial solution, the starting optical density (OD) was measured from
each culture tube using a NanoDrop 2000 (ThermoFischer Scientific, Waltham, MA).
Diluting the P. putida in LB was performed to ensure consistent starting OD between
experiments. 1.25 mL of P. putida in LB were added to each well using 12-well plates.
Contact layers were submerged in each well. The OD was measured from each well at the
short and long term intervals as mentioned in the GS release study.
Disk Diffusion Method
P. putida was cultured in sterile LB and incubated at 37°C and 5% CO2 and agitated
on a shaker plate overnight. After resuspension, the starting OD was measured. The
bacterial solution was diluted 1,000-fold with sterile deionized water. 100 µL of the new
diluted bacterial solution was added to an agar plate. Using plating beads, the solution
containing P. putida was homogeneously spread over the entire agar. 0.75-cm diameter
contact layers of each GS treatment were placed flat in the center of the agar plate. Each
plate was incubated at 37°C and 5% CO2 overnight. The zone of inhibition (ZOI) was
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determined by measuring the diameter of the region where there was no apparent growth
of P. putida around the contact layer.
Biocompatibility and Cell Adhesion Analyses
Biocompatibility and cell adhesion tests were performed simultaneously using
AlamarBlueTM (Thermo Scientific Remel Inc. Lenexa, KS) and Quant-iTTM PicoGreenTM
(Thermo Fischer Scientific Life Technologies Corporation, Eugene, OR) assays to
determine whether the material and GS elution of the contact layers promoted cell growth
and attachment. Both AlamarBlueTM and Quanti-iTTM PicoGreenTM assays measure the cell
growth through metabolic response and DNA quantification, respectively.
The mesenchymal stem cells used in this study were murine bone marrow stromal
D1 cells. Cells were first cultured in T-75 polystyrene culture flasks (Corning; Fischer
Scientific, Waltham, MA, USA) to confluency in a growth medium cocktail consisting of
DMEM, FBS, and AA at 37°C and 5% CO2. Growth medium was changed every two to
three days. Cells were removed from their flask via trypsinization and split into a 24-well
non-treated, low attachment polystyrene culture plates (Corning; Fisher Scientific,
Waltham, MA, USA) with the starting cell density at 17,000 cells/well. Each contact layer
was submerged over the cells immediately after cell splitting. Cell proliferation was
analyzed at time points 0, day 1, day 3 and day 5.
AlamarBlueTM Assay
At each time point, 65 µL of AlamarBlueTM dye was added to each well and
incubated at 37°C and 5% CO2 for three hours. 200 µL was taken from each well and added
to a 96-well plate (Corning; Fisher Scientific, Waltham, MA, USA). The plate was read
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using a Synergy MX Multi-Mode Reader at an excitation wavelength of 560 nm and an
emission wavelength of 590 nm.
Quant-iTTM PicoGreenTM Assay
The remaining DMEM solution with AlamarBlueTM dye was removed, and each
well was rinsed with 600 µL of 1X PBS. To obtain double-stranded DNA in solution, the
PBS was removed, and cells were ruptured via trypsinization for a two minute incubation
period and sonication of each well for 20 seconds. The trypsin solution was centrifuged
and removed. The dsDNA was resuspended using TE buffer. Samples were frozen at -20°C
until analysis. After each time point, samples were thawed. 1 mL of Quanti-iTTM
PicoGreenTM dsDNA reagent was added to each sample. A standard curve was created, as
seen in Table 2.3, to determine the relation between fluorescence and dsDNA
concentration.
Table 2.3. Standard curve concentrations (ng/mL) for dsDNA detection
Standard curve
concentrations

0

1

10

100

1,000

Each standard and unknown sample was added to a 96-well plate. The plate was
read using a Synergy MX Multi-Mode Reader at an excitation wavelength of 480 nm and
an emission wavelength of 520 nm.
PEG Surface Treatment
The treatment of polyethylene glycol (PEG) was added as a thin monolayer to the
PLLA/GS contact layers to introduce non-adhesive properties. 400 mg of 1500 Da or 4600
Da PEG (Sigma-Aldrich, St. Louis, MO USA) was dissolved in 10 mL of sterile deionized
water. 1 mg of GS was added to the solution, to obtain a GS starting concentration of 100
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µg/mL, needed to achieve the antibacterial properties above the MIC. Contact layers were
submerged in 2 mL of the PEG/GS solution and left to sit for 48 hours. The resulting
gelatinous contact layers were left to dry overnight.
X-ray Photoelectron Spectroscopy
To confirm the surface treatment of PEG, 1cm x 1cm x 0.32 mm PEG/PLLA
contact layers were loaded, separately, into a sterile load-lock chamber. Once the pressure
registered 10-5 Pa, the samples were transferred to the analysis chamber. After the pressure
dropped to 10-7 Pa, the spectra of each sample was collected.
LIVE/DEADTM Analysis
Fibroblasts used in this study were from a murine 3T3 cell line. Cells were first
cultured in T-75 polystyrene culture flasks to confluency in a growth medium cocktail
consisting of DMEM, FBS, and AA at 37°C and 5% CO2. Growth medium was changed
every two to three days. Cells were removed from their flask via trypsinization and split
into a 24-well non-treated, low attachment polystyrene culture plates with the starting
density at 17,000 cells/well. Each PEG treated contact layer was submerged over the cells
immediately after cell splitting. Cell proliferation and attachment were analyzed at days 1,
3, and 5. Cell media from each treatment was removed and cells were rinsed with 100 µL
of 1XPBS. 200 µL of staining solution containing calcein and ethidium homodimer
(Invitrogen Ltd., Paisley, UK) diluted in 1XPBS was added to each well, and incubated at
37°C and 5% CO2 for 30 minutes. Cells were imaged using transparent, Texas Red and
green fluorescent filters.
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Antibacterial Efficacy Verification of PEG Treated Contact layers
Seven 2-cm diameter contact layers were cut and cleaned using the above cleaning
protocol. Contact layers were then treated with 2 mL of 40 mg/mL PEG and 100 µg/mL
GS solutions and let to sit at ambient conditions for two days. Each contact layer was set
to dry overnight. P. putida was inoculated in 4 mL of sterile LB and incubated at 37°C and
5% CO2 overnight. Three culture tubes were made to generate enough cultured bacteria for
each contact layer treated with varying concentrations of GS. The culture tubes were set
on an agitator plate to prevent pellet formation while promoting homogenous mixture of
P. putida in LB. After resuspension of bacterial solution, the starting OD was measured
from each culture tube using a NanoDrop 2000. Diluting the P. putida in LB was performed
to ensure consistent starting OD between experiments. 1.25 mL of P. putida in LB were
added to each well using 12-well plates. Contact layers were submerged in each well. The
OD was measured from each well at the short and long term intervals as mentioned in the
previous antibacterial efficacy study.
Statistical Analysis
Elution and antibacterial effects considered all 20 combinations of contact layers to
determine differences between yarn shape, GS incorporation method, and GS
concentration. Given the factorial nature of this study, all 20 of the potential variable
combinations were not tested for biocompatibility. All analyses included three replications
(n=3) and were analyzed using the T.Test function using Microsoft Excel program and a
level of significance, 𝛼, of 0.10.
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Results and Discussion
Cross Sectional Area of 4DG Mono- and Multifilament Yarn and the Knitted Contact Layer

This study includes a factorial set of treatments based on yarn geometry, GS
concentration, and incorporation method to determine the optimal antibacterial properties
for infection management in chronic wounds. PLLA was chosen as the material skincontact layer due to its versatility in extruding shaped yarns, mechanical properties
conducive to knitting, and antibiotic delivery mechanism. Images of the cross-sectional
area of the 4DG monofilament and yarn, as well as the knitted contact layer are shown in
Figure 2.4. Figure 2.4B shows each of the 36 4DG filaments making up the shaped yarn,
used in the skin-contact layer. The contact layer in Figure 2.4C specifically depicts the
geometric shape during the knitting process as well as the breathability of the layer.

Figure 2.4: (A) Scanning electron microscope (SEM) image of a wicking fiber. Adopted
with permission from John Wiley and Sons88. (B) Cross sectional area of 4DG yarn,
where red and blue outlines represent macro- and microcapillaries. (C) Knitted contact
layer of round yarn.
Short Term GS Elution Profile from GS Incorporated Contact Layers
GS was incorporated into the contact layer via diffusion in GS solutions
overnight. The effect of fiber geometry was tested by analyzing the elution profile from

63

both round and 4DG yarn at various time points. The short-term intervals were evaluated
during the first nine hours. Figure 2.5A shows that each treated yarn had a burst release of
GS during the first four hours, with yarns of increasing treatment concentrations releasing
at higher rates. Additionally, it can be seen in Figure 2.5B that the 4DG yarn (solid) for
each treatment released higher elution concentrations over time in comparison to round
yarn (checkered), although the difference in release from round and 4DG yarn for each
concentration treatment at each hour is not considered different, with the exception of the
10,000 µg/mL treatment (p = 0.029). The 4DG shaped yarn released higher amounts of GS
as a result of uptaking more GS due to a larger surface area when soaking.

**

**

**

Figure 2.5: (A) Cumulative release of GS elution from all round and 4DG contact layers
loaded via the soaking mechanism over short-term intervals. (B) Burst release of GS at
short-term intervals from all round and 4DG treated contact layers.
A comparison between diffusion, heat-enable diffusion, and dyeing methods of GS
incorporation can be seen in the release profile using round yarn in Figure 2.6. The heatenabled treatment exceeded the release of its corresponding diffusion and dyed treatments,
and was significantly different for the 10µg/mL treatment when compared to the dyed
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treatment (p = .00411), and 100 µg/mL treatment when compared to both the dyed (p =
.000579) and diffusion (p = .000006) methods. The diffusion method remained
significantly different for both 10 µg/mL (p = .00167) and 100 µg/mL (p = .01965)
treatments when compared to the dyed treatment.

Figure 2.6: Cumulative release profiles of GS from round yarn treated via diffusion,
heat-enable diffusion, or dyed methods of incorporation over short-term intervals.
The binding affinity between a dye and a fabric depends heavily on the structure of
the dye and the interaction between them. GS has a large 3-dimensional structure and the
hydrogen bonds within the GS chemical structure may make it challenging to bind to the
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polar bonds found in PLLA, thus providing a difficult path for GS molecules to enter the
polymer chains of PLLA .
Antibiotic Efficacy of GS Incorporated Contact Layers via Liquid Broth and Disk Diffusion
Analysis
Contact layers of all shape, method, and concentration combinations were
submerged in liquid cultured P. putida. The OD was measured at both short and long term
intervals to reflect the corresponding elution profile. The percent growth was then
determined using the ratio of the current OD reading to that of the initial OD reading (t=0).
The effects of antibiotic release as a function of shape and method can be shown in Figure
2.7. It appears that although the 4DG shape of the yarn contributes to a higher release
profile of GS when compared to round yarn as indicated in the elution study, the burst
effect above the indicated minimum inhibitory concentration (MIC) (~1 µg/ml)89 of GS
from each shaped yarn seemed to have a similar impact on the inhibition of P. putida as
shown in Figure 2.7A. Therefore, at the chosen treatments, efficacy remained concentration
independent. Similarly, although contact layers treated with GS by method of heat-enabled
diffusion released GS at higher rates, the antibiotic efficacy of contact layers by the
diffusion and heat-enable diffusion method of incorporation remained the same, as seen in
Figure 2.7B, since both treatments released GS at or above the MIC against P. putida. This
excludes the dyed treatment (Figure 2.7C), since there remained little to no GS release, and
therefore, the growth of P. putida was not inhibited by the dyed method of incorporation.
The amount of GS that the contact layer initially contained could have played a role
in the antibacterial behavior. During the short-term intervals, all treatments contributed to
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a bactericidal effect, where the bacteria growth rate decayed over time. Moving into the
longer-term intervals, contact layers treated with concentrations below 1,000 µg/mL GS
contributed to a bacteriostatic effect, and bacteria growth continued to stay dormant.
Contact layers treated with concentrations at or above 1,000 µg/mL seemed to have a slight
burst in growth after 24 hours. This may be caused by antibacterial resistance as new
generations of P. putida formed over time.
There remains an increase in growth of P. putida, as seen in Figure 2.7C for all
dyed treatments over both short and long time intervals, verifying the lack of GS uptake
and elution.
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Figure 2.7: Antibiotic efficacy profiles during both short and long term intervals. (A)
Percent growth of P. putida from contact layers of each shaped yarn treated with GS by
method of diffusion. (B) Percent growth of P. putida from contact layers of round shaped
yarn treated with GS by diffusion or heat-enable diffusion method of incorporation. (C)
68

Percent growth of P.putida from contact layers of round yarn treated with GS by dyed
method of incorporation.
Contact layers of all treatments were placed on agar cultured P. putida. At 24 hours,
the zone of inhibition (ZOI) was determined by measuring the diameter across the area
where there were no bacteria colony forming units (CFU) present. The combinational effect
of yarn shape and GS soaking concentration is shown in Figure 2.8. Unlike the liquid broth
antibacterial analysis, the disk diffusion study showed that the ZOI was dependent on
concentration treatments. As concentration increases by a factor of 10, the ZOI increases
linearly as indicated in Figure 2.8I. There is no significant impact on the ZOI from the
shape of the yarn similar to the efficacy profile in liquid cultured P. putida.

Figure 2.8. (A-D) . (A-D) P. putida exposed to contact layers with round yarn treated via
diffusion method with treatment concentrations of (A) 10 µg/mL , (B) 100 µg/mL, (C) 1,000

µg/mL, and (D) 10,000 µg/mL. (E-H) P. putida exposed to contact layers with 4DG yarn
treated via diffusion method with treatment concentrations of (E) 10 µg/mL , (F) 100

µg/mL, (G) 1,000 µg/mL, and (H) 10,000 µg/mL. P. putida exposed to contact layers with
round or 4DG yarn treated via diffusion and varying treatment concentrations of GS.
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The combinational effect of GS method of incorporation and GS concentration is
shown in Figure 2.9. As concentration increases, the ZOI increases significantly (p =
0.0343), with the exception of the dyed method of incorporation. There remains no
difference in ZOI between diffusion and heat-enabled diffusion methods of GS
incorporation. There appeared no ZOI for the dyed treatment indicating statistical
differences between diffusion (p = 0.155) and between heat-enable diffusion (p = 0.127).

Figure 2.9. (A-C) P. putida exposed to contact layers with round yarn treated via (A)
diffusion, (B) heat-enabled diffusion, and (C) dyed methods of incorporation for treatment
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concentrations of 10 µg/mL. (D-F) P. putida exposed to contact layers with round yarn
treated via (D) diffusion, (E) heat-enabled diffusion, and (F) dyed methods of
incorporation for treatment concentrations of 100 µg/mL. (G) P. putida exposed to contact
layers with round yarn treated via diffusion and heat-enabled diffusion with treatment
concentrations of 10 µg/mL and 100 µg/mL.
Biocompatibility and Cell Adhesion
Contact layers treated with varying GS concentrations incorporated via diffusion
method were submerged in bone marrow stromal D1 cells in DMEM to test cell metabolic
activity, viability, and cell preferential adhesion. Due to the large factorial experimental
design, cells were only exposed to contact layers of round yarn treated via diffusion method
of 1 µg/mL, 10 µg/mL, and 100 µg/mL. Non-treated 24-well plates were used to prevent
cell attachment for a better indication of cell adhesion preference. The cell metabolic
activity was measured via AlamarBlueTM fluorescent agent. Normalized metabolic activity
is described as the percent viability. Each experimental condition’s percent viability was
calculated using the fluorescent readings of the experimental condition and the negative
control condition, which included the cultured D1 cells without any presence of a contact
layer. Figure 2.10A shows the percent viability of the total number of cells exposed to the
GS treated contact layers via diffusion mechanism. Each treatment had a percent viability
at or above 100%, relative to the negative control condition. The cells had a healthy
response to the release of GS concentration for concentrations between 1 µg/mL and 100
µg/mL at all time points, including the initial burst of GS release.
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In addition to metabolic activity, DNA concentration was measured using QuantiTTM PicoGreenTM Assay. A standard curve of known DNA concentrations was used to
calculate the DNA content from cells adhered to either the contact layer or the well plate
in order to determine cell attachment behavior. Each experiment contained a well (blank
condition) that contained actively growing D1 cells without the presence of a contact layer.
Figure 2.10B shows the increase in DNA concentration from cells adhered to the contact
layer or well plate locations over five days for all treatment concentrations. There is a slight
decay in DNA concentration after Day 3 for the blank condition indicating over-confluency
and some cell death. It appears that for each concentration condition, cells preferred to
attach to the contact layer as a result of high surface area for adhesion and lack of
pretreatment on the polystyrene 12-well plates. This particular study is important because
it shows that due to PLLA’s relative hydrophobicity and unique geometry, a surface
treatment is needed to prevent cell attachment for granulation tissue repair.

Figure 2.10: (A) Percent viability of total number of D1 cells exposed to GS treated
contact layers via diffusion mechanism. (B) DNA concentration of D1 cells adhered to
either the GS treated contact layer or the well plate.
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XPS Analysis
PEG was chosen as the surface treatment due to its relative surface resistance to
protein and non-specific cellular binding specifically for the prevention of debriding the
delicate repaired tissue when changing a dressing90. The method for treating the surface of
contact layers with PEG was confirmed in XPS analysis. Figure 2.11A shows the survey
spectra of the PLLA/PEG contact layers indicating that there are only two elements within
the sample, carbon and oxygen at binding energies of approximately 285eV and 540eV,
respectively. Figure 2.11B-D depicts the normalized peaks of the (B) PLLA contact layer,
(C) PLLA/1500 PEG contact layer, and (D) PLLA/4600 PEG contact layer, respectively.
The contact layer with PEG shows an additional peak at approximately 286 eV, where
there is a C-O bond. As the density of the PEG increases, the peak area of C-O increases.
Therefore, the total peak area of O-C=O, C-C-C=O and C-C present in PLLA, decreases
in contact layers treated with PEG by 15% and 34% for PEG 1500 and PEG 4600,
respectively.
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Figure 2.11 : (A) XPS survey spectra. Peak fitting of (B) PLLA contact layer, (C)
PLLA/1500 PEG contact layer, and (D) PLLA/4600 PEG contact layer.
LIVE/DEADTM Adhesion Analysis
GS incorporated PLLA and PLLA/PEG contact layers were exposed to 3T3
fibroblast cells. After exposure for 24, 72, and 120 hours, the cells adhered to either the
well plate or contact layer were stained with diluted ethidium homodimer and calcein.
Shown in Figure 2.12, green fluorescently labeled cells indicate healthy, viable fibroblasts
and red fluorescently labeled cells indicate dead fibroblasts. At each time point for all
conditions, there remained nearly 100% viability indicating that the PEG/GS incorporated
contact layers (cleaning method, PLLA, PEG, and GS elution) does not negatively impact
cell viability. Additionally, there is an increase in cell growth for all treatments over time.
The control PLLA contact layer depicts some cell attachment to the contact layer over time.
When the contact layer is treated with either PEG 1500 and 4600, there is less visual cell
attachment, and the confluency on the cell well plate is much greater than that of the control
PLLA contact layer.
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Figure 2.12. LIVE/DEADTM images of fibroblasts exposed to PEG treated GS
incorporated PLLA contact layers (PEG Da : GS diffusion concentration (µg/mL )) .
Antibacterial Efficacy with PEG treated contact layers
The antibacterial efficacy of the PEG treated GS PLLA contact layers was
reexamined, as seen in Figure 2.13, to confirm that the PEG surface modification did not
negatively impact bacterial inhibition. The microscopic surface treatment still allowed for
release of GS. The amount of GS released was above the MIC as indicated by the
bacteriocidal and bacteriostatic effect in both short and long term intervals.
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Figure 2.13: Percent growth of P. putida after exposure to PEG treated GS incorporated
PLLA contact layers.
Conclusion and Limitations
This work explored the combination of GS incorporated skin contact layers of three
proposed methods of incorporation and yarns of two different cross-sectional geometries.
The purpose for adding antibiotic into the yarn in various mechanisms was to develop an
effective release profile needed to kill and inhibit growth of bacteria in a way that is
simultaneously conducive for healthy cells to replace the wounded skin tissue.
Our results indicated that two out of the three proposed methods of incorporation
were conducive to inhibiting bacteria growth in both bactericidal and bacteriostatic trends
for short and long term time points, respectively. Due to instrument limitations, GS could
not be directly added to the polymer prior to extrusion, and therefore, alternative
approaches, such as diffusion and dyeing were proposed. The dyeing mechanism could be
reconsidered using alternative procedures by optimizing time and temperature in
exhaustion dyeing. If the GS molecular structure remains complex for dyeing, methylene
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blue could be used as an alternative antibiotic; however the ideal elution profile and
antibacterial efficacy analysis are not guaranteed for a wide spectra of pathogens.
Additionally, the elution profile for optimal concentrations did not negatively
impact healthy cell metabolic activity. However, fibroblasts gravitated towards the skin
contact layer indicating the need for a non-adherent surface treatment. The influence of
PEG as a surface treatment on the skin-contact layer with a non-adhesive layer as well as
its impact on antibiotic elution and antibacterial efficacy can prevent unnecessary autolytic
debridement while contributing to antibacterial efficacy. Outcomes from this work provide
insight into incorporating optimal concentrations of antibiotic into a medical textile skincontact layer, while creating a healthy environment for new granulation tissue to start
repairing and remodeling the injured site.
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CHAPTER THREE
DESIGN AND DEVELOP THE FOAM-BASED ABSORPTIVE AND MOISTURE
WICKING LAYERS FOR FLUID TRANSPORT
Introduction
After controlling infection, moisture management is the second task for treating
diabetic chronic wounds. Wound exudate is the drainage produced by the body in response
to tissue damage and can have many beneficial effects towards wound healing, such as
angiogenic and cell proliferative stimulating effects1. It is a derivative of blood serum with
high protein content and tissue growth factors required in the healing process. It also
contains necrotic tissue and white blood cells. Most wounds produce exudate drainage, but
some, such as diabetic wounds experience overwhelming volumes due to the chronic nature
of the wound, location, pressure, infection, and depth. Neuropathy and vascular disease
enable excessive wound exudate. Many studies argue that a moist environment is more
favorable for wound healing2. Others have noted that excessive drainage can complicate
healing and cause maceration1. Uncontrolled volumes can drown the wound and cause
periwound maceration, deteriorating the tissue and preventing a conducive environment
for repair and remodeling. That being said, it is imperative to control for high levels of
exudate in order to prevent worsening conditions while also promoting tissue repair and
remodeling with a moderate volume, so as not to dry out the wound.
There exists a wide array of commercialized absorptive dressings, many with both
absorptive and wicking properties. However, one of the major obstacles present in
developing an absorptive dressing from an engineering perspective as well as choosing the
best dressing from a clinical setting, is the ability to control for excess exudate levels
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without saturation, maceration, and multiple dressing changes3-5. A proper absorptive
dressing must combine both absorptive and wicking qualities to effectively and evenly pull
moisture away from the wound bed as well as evaporate into the external environment in
order to prevent saturation.
Absorptive Dressings
Mentioned in earlier chapters, absorptive dressings are typically classified into
polyurethane (PU) foam-, alginate-, and hydrofiber-based dressings. PU foam possesses
advantages of tunable softness, flexibility, breathability, and the ability to absorb moderate
to high levels of exudate6. It is also important to consider compression that can withstand
weight bearing activities as well as contribute toward patient comfort. PUs contribute much
to thermal insulation and comfort. They are easily cut to shape. Mentioned previously for
its unique antimicrobial property containing methylene blue and gentian violet, Hydrofera
Blueâ (Hydrofera, Essex, CN) is a multilayer dressing comprised of PU foam and polyvinyl alcohol used for rapid wicking and exudate retention7. ALLEVYN Compression
Dressing (Smith&Nephew, London, UK) is also a common absorptive dressing made of a
self-adherent PU matrix, while also providing permeation to oxygen and water vapor8.
Hydrofiberâ technology (ConvaTec, Deeside, UK) modernizes wound care by its
ability to absorb large amounts of wound exudate while maintaining moisture for wound
healing. It primarily is composed of sodium carboxymethylcellulose, incorporated into a
form of fabric9. This material can absorb large amounts of exudate and eventually
transform into a gel, which creates an ideal environment for wet wounds. Hydrofiberâ
technology was invented by ConvaTec as Aquacelâ (ConvaTec, Deeside, UK)10. Not only
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does it possess absorptive technology, but it can be shaped into different geometries for
different anatomical areas. Versivaâ XCâ (ConvaTec, Deeside, UK) is another dressing
produced by ConvaTec that has adapted the Hydrofiberâ technology11.
Alginate-based dressings incorporate calcium alginate into a loose fabric.
Uniquely, the calcium ions in the dressing interact with sodium ions in wound exudate,
causing the dressing to transform into a gel-like substance12. Algicellâ (Integra
LifeSciences, Billerica, MA) is a common alginate based dressing, comprised of
mannuronic (high gelling) and guluronic (high wet-strength) alginic acids. It is typically
used for highly exudated wounds and can prevent bacterial infection throughout its unique
ionic transfer technology used to deliver low levels of silver13.
Hydrofiberâ and alginate technology modernize wound care by interacting with
wound exudate. The disadvantage of both technologies is that they can easily saturate in
gel form. The dressing is not reversible, so once in gel form, the dressing cannot easily dry.
Additionally, it does not provide any rapid wicking capabilities, so when saturated, the
only option requires a dressing change. This becomes problematic, especially for highly
exudated diabetic foot ulcers, because it could lead to several dressings per week that
exceed insurance’s policy for dressing reimbursement. Ultimately, this becomes expensive
for the patient. Finally, the gelatinous form that it creates may not be conducive to
compressive properties required for foot ulcers.
Polyurethane Foam and its Desired Properties
Due to its ease in manufacturing and versatile usage for both wet and dry wounds,
PU was chosen as the absorptive layer of our multi-phasic wound dressing. Additionally,

87

preliminary research indicates that PU foam saturates at a lower rate than many
Hydrofiberâ and alginate absorptive dressings. PU’s functions can be manipulated by
altering the ratio of hard and soft chains of the polymer as well as physical and chemical
blowing agents, such as pentane, hexane, and acetone and water to expand the polymer by
CO2 produced6. This will ultimately alter the density, compression, and porosity of the
foam for absorptive purposes.
PU foam is designed to absorb wound moisture, but the foam itself does not have
moisture wicking capabilities that transfer fluid into the open air, allowing for longer
durations before dressing changes. Uniquely, the textile industry has developed a
technology to advance fabric by addressing moisture wicking capabilities. Fiber cross
sections can create channels with high capillary pressure that allows for transporting liquid.
In this aim, this technology can be used to modernize wound care by transporting exudate
from the absorptive layer through a wicking textile layer and into the external environment,
resulting in a longer-lasting dressing with fewer dressing changes14. Additionally, a
secondary dressing can be used in between the skin-contact layer and absorptive layer to
evenly spread out exudate so as not to cause maceration in one area of the dressing.
Moisture wicking
Wicking can occur due to the fact that fibers possess capillary spaces that can
displace liquid15. Typically, moisture wicking fabrics include synthetic fibers such as
polyester or nylon. These two particular polymers are useful in wicking as they are made
from materials with a particular chemistry similar to plastics. Instead of moisture absorbed
through the fiber, it sits in the channels of the fiber and moves around the fabric by traveling
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along the weave. Ultimately, the moisture reaches the outside of the fabric and evaporates
into the air. Wicking fabrics dry at faster rates because they do not absorb moisture16. There
are many factors that can alter the rate of wicking, such as fiber material, geometry, fiber
count, twisting level and tension. Wicking also occurs in-plane where there is a spreading
of the liquid in the textile layer and through-plane where liquid is transported from surface
to the other side of the fabric15.
The combination of fabric weight, fiber fineness, fabric construction, and garment
design all impact the ability to transfer moisture from the skin to the external
environment17. The smaller the channel, the faster moisture can be transported through the
fabric. This is due to the fact that there is higher capillary pressure. In a larger channel or
pore, a greater amount of liquid can be retained but the distance is limited due to greater
capillary diameter. Smaller channels influence the speed of liquid spreading. To control for
wound exudate, the size of the channel can be optimized to control moisture wicking
without drying out the wound. As mentioned previously in Chapter 2, some common fiber
cross-sections that are useful for increasing surface area and moisture wicking are the
trilobal, circular hollow fiber, lobular, star shaped, square with voids, and four-deep
grooved some of which can be seen in Figure 3.118-20.
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Figure 3.1: Cross section of multifilament yarns composed of fiber with (A) hollow round,
(B) trilobal, (C) cruciform, (D) star, (E) hollow fiber, and (F) 4DG shapes18-20.
For our purposes, 4DG was chosen as the cross section because of its smaller
channels and greater capacity to remove more viscous fluids from higher channel pressures.
4DG is also unique to Clemson University. In January of 2000, Eastman Chemical
Company donated this technology to the Clemson University Research Foundation. The
license has been provided by Fiber Innovation Technology, Inc. (FIT) to manufacture and
market the 4DG fiber. What makes this design unique is its high surface area, 300% that
of round fiber, its preferred bending modulus to provide softness, and the four uniquely
shaped ducts that move fluid spontaneously20. Examples of potential applications for this
unique design are listed in Table 3.1, many of which are for the purpose of fluid movement.
Table 3.1 Examples where 4DG fibers are used in industry20
Athletic Field Surfaces
Ink Cartridges
Pap Smear Swabs
Condensate Collectors
Mascara Brushes
Sweat Bands
Fabric Softener Strips
Military Gear/Apparel
Shoe Liners and Socks
Filter Media
Mops and Brushes
Throat Swabs
Humidifiers
Orthopedic Cast Liners
Wound Care
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Research Objectives
Specific research objectives for this work included the following items:
1. Develop a PU foam absorptive layer that provides ideal compression and optimal
absorption
2. Perform a comparative analysis of the PU foam layer to three commercialized
absorptive dressings (i.e. alginate, hydrofiberâ, and foam)
3. Develop a woven wicking layer that is able to transfer moisture to prevent
maceration while dispensing into the external environment.
Materials and Methods
PU Expandable Foaming Process
Parts A and B from FlexFoam-iT! PU foam kits IV, V, and 6 (Smooth-on Inc., East
Texas, PA), each with a density of 4, 5, and 6 lbs/ft3, respectively, were combined using a
plastic mold with lubricant (Super Slick Stuff, Protexall Products, Inc., Pearl River, LA )
to prevent sticking to the mold. Parts A and B were mixed at speeds 500 to 3000 rpm, and
the foam was cured for 1 hour before handling. Foams were sectioned into 5 cm x 5cm x 1
cm squares, and then dried overnight in a vacuum oven at 70°C.
Serum Extraction
To obtain serum, blood was collected from two pigs in 10 mL Red/Grey Serum
Separation Tubes (BD Vacutainer, Franklin Lakes, NJ) and allowed to clot at room
temperature for 30 minutes. Each tube was centrifuged at 1500 rpm for 8 mins to ensure
proper separation. The supernatant (serum) was then collected and frozen at -20°C until
usage. Upon usage, serum was thawed to room temperature.
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Compression
Compression was tested using an Instron Mechanical Tester. The compressive
elastic modulus and compressive stress at maximum load was recorded using a 500 N load
cell.
Absorption Analysis
Following the drying period, foams were cooled in a vacuum chamber for 1 hour.
The initial weight of each foam was measured. Foams were then added to a reservoir of 50
mL of either H2O or porcine serum. The wet weight, which included the weight of the foam
and the absorbed liquid was measured at 1-6 hours, 9 hours, 12 hours, 24 hours, and every
24 hours after leading up to 7 days. After every 24 hours, 10 mL of water was added to
each sample. The absorption after 24 hours was calculated using Equation (1), and the
absorption rate was found over a period 7 days.

𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 (1): 𝐴𝑏𝑠𝑜𝑟𝑝𝑡𝑖𝑜𝑛 =

(𝑤𝑒𝑖𝑔ℎ𝑡 (𝑡) − 𝑤𝑒𝑖𝑔ℎ𝑡 (0))
𝑥 100
(𝑤𝑒𝑖𝑔ℎ𝑡(𝑡))

Comparative Absorption Analysis with Serum
The comparative absorption analysis was also conducted over 5 days using 12.5
mL of serum. FlexFoam-iT! PU foam kit V was chosen as our PU absorptive layer and
compared to three different absorptive, commercialized dressings: a Hydrofiberâ,
(Aquacelâ), an alginate (Algicellâ), and a PU+PVA foam (Hydrofera Blueâ). All
dressings were cut into 2.5 cm x 2.5 cm squares. To control for evaporation, a separate well
with just serum was observed and the volume of liquid was measured at each time point.
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The initial weight of each dressing and foam was measured, and both the wet weight and
volume of serum leftover was measured at 1-6 hours, 9 hours, and 24 hours and every 24
hours up to 5 days. Additionally, after every 24 hours, 2.5 mL of serum was added to each
well, including the evaporation well, to model continuous exudate formation. Wicking
from the commercialized dressings was considered and calculated using the Equation (2).
𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 (2): 𝑊𝑖𝑐𝑘𝑖𝑛𝑔 (𝑡)
= 𝑖𝑛𝑖𝑡𝑖𝑎𝑙 𝑑𝑟𝑒𝑠𝑠𝑖𝑛𝑔 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑡) − (𝑎𝑏𝑠𝑜𝑟𝑝𝑡𝑖𝑜𝑛 (𝑡) + 𝑠𝑒𝑟𝑢𝑚 𝑤𝑒𝑖𝑔ℎ𝑡 (𝑡)
+ 𝑒𝑣𝑎𝑝𝑜𝑟𝑎𝑡𝑖𝑜𝑛 𝑟𝑎𝑡𝑒 (𝑡))
Initial dressing weight (t) = weight of the dressing (t) + weight of the serum in the well (t)
+ any serum added after 24 hours
Absorption (t) = dressing with absorbed serum (t)
Serum weight (t) = weight of the serum that remains in the well
Evaporation rate (t) = the weight of the serum that evaporates from the evaporation well
over 24 hours
Water and Serum Contact Angle
Contact angle measurements were measured using both water and serum to
determine hydrophobicity and absorption rate. Contact angle is a measure of the wettability
of a solid by a liquid. When there is an interface between a solid and liquid, the angle
between the surface of the liquid and the tangential line is called the contact angle. If the
angle is 0°, the material is considered completely wettable. If between 0° and 90°, the
material is considered wettable, and if over 90°, the material is not considered wettable.
PU foam of 0.4 cm thickness was placed on the stage of a Drop Shape Analyzer
(DSA25, Kruss, Matthews, NC, USA). A 2 µl drop of either water or serum was dropped
on top of a flat surface of the foam. The initial contact angle was measured. Additionally,
the angle was measured every 30 secs for 20 mins using the time sequencing element.
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UVO Surface Treatment
To increase surface wettability of the PU foam, foam layers were exposed to
varying time duration of ultra violet ozone (UVO). Using a UV-Ozone cleaner (Novascan
Technologies Inc., Boone, IA USA) foam layers were exposed to UVO for 15, 30, and 60
minutes. Immediately following exposure, the contact angle and absorption analysis tests
were conducted.
Extrusion Process for Wicking Layer
PLLA (Jamplast, Inc. Ellisville, MO USA) was melt-spun into 36 filaments each
with 4 deep-grooved (4DG) cross-sections using a large-scale continuous twin screw meltextruder and spinneret system (Hills Incorporated, Melbourne, FL). Differential scanning
calorimetry (DSC) was used to obtain the glass transition (Tg) and melting temperature
(Tm) needed to derive the extruder’s four heating zones. Final heating zones for PLLA were
185°C, 205°C, 220°C, and 210°C. The fiber diameter was controlled by the pump speed at
the extruder outlet and the drawing rate of the sequential rollers and spool used to collect
the fiber post-extrusion. The fibers were extruded at a 20 rpm pump motor speed resulting
in 300 µm yarn.
Weaving Process
The second PLLA layer was braided in the full load regular pattern (1 over 2 under
2) using a 25.4mm diameter mandrel. The multifilament was braided at 15 pics per inch
using a KL80d carrier with tension and ratchet springs of 0.45 mm and 0.3 mm,
respectively. Four rollers were used at a speed of 35 rpm.

94

Vertical Wicking and Spot Test Analysis
7 cm PLLA braids were cut and dried in a vacuum chamber for 30 minutes. Porcine
serum was thawed. A solution of 3 mL of serum and 1 mL of trypan blue dye (Corning;
Fisher Scientific, Waltham, MA, USA) was used as the 5 mm tall wicking absorbate and
added to a 100 mL beaker. The PLLA braid was added to the beaker and the stopwatch
was started immediately after. Once the dyed serum solution reached 7 cm, the time
stopped.
Statistical Analysis
All analyses included three replications (n=3) and were analyzed using the T.Test
function using Microsoft Excel program and a level of significance, 𝛼, of 0.10.
Results and Discussion
This study includes the design, moisture absorption profile, and wicking analyses
of the absorptive foam and moisture wicking layers of the multilayered wound dressing.
PU foams IV, V, and 6 with densities of 4 lb/ft3, 5 lb/ft3, and 6 lb/ft3, respectively, were
made at varying mixing speeds to determine any effects on absorption and compression.
PU Foam Micro- and Macrostructure
Images of the PU foam micro- and macrostructure are shown in Figure 3.2. Figure
3.2A depicts the surface of PU foam V using scanning electron spectroscopy. Figure 3.2B
depicts the pore sizes of PU foam V. The foam layer in Figure 3.2C shows the relative size
and macrostructure used in the absorptive and contact angle analyses.
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Figure 3.2: (A) Scanning electron microscope (SEM) image of PU Foam V. (B) Pore size
of the PU Foam V at surface. (C) Macrostructure of PU Foam V.
Compression Testing
PU foam IV is marketed as “tuff stuff”, while PU foam 6 is described as “pillow
soft”. The compressive elastic modulus was measured on each PU foam type at mixing
speeds 500 and 3000 rpm and can be seen in Figure 3.3. Due to the large standard deviation
for PU foam 6, there remained little to no significant difference than IV and V with the
exception of V at mixing speed 500 rpm (p = .093). There was significant difference
between PU foams IV and V at 3000 rpm (p = .0000136). For both PU foams IV and V,
there remained significant difference in mixing speeds (p = .017 and .064, respectively).
Although with some variation seen, it can be concluded that density and mixing speed,
altering porosity of the foam, may contribute to compressive elastic modulus and
ultimately, comfort and durability of the foam.
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Figure 3.3: Compressive Elastic Moduli of PU foams IV, V, and 6
at mixing speeds 500 and 3000 rpm.
Absorption Analysis
The absorption and absorption rate of each foam was measured and can be seen in
Figure 3.4. Because the difference in densities between PU foams remained small and there
remained inconsistency in overall trend of compressive elastic modulus, there showed no
significant difference in absorption. Absorption of PU foam V at mixing speeds between
500 rpm and 3000 rpm (Figure 3.4A), and PU foams IV and 6 at mixing speeds of 500 and
3000 rpm (Figure 3.4B) were analyzed by calculating the increase in weight percent over
24 hours. The absorption rate was measured over 7 days for each mixing speed (Figure
3.4C) and foam density (Figure 3.4D).
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Figure 3.4: (A) Absorption of PU foam V as a function of mixing speeds over 24 hours.
(B) Absorption rate of PU foams IV, V, and 6 at mixing speeds 500 and 3000 rpm over 24
hours. (C) Absorption rate of PU foam V as a function of mixing speeds across 7-days.
(D) Absorption rate of PU foams IV, V, and 6 at mixing speeds 500 and 3000 rpm across
7-days.
There didn’t appear to be any difference in initial absorption and rate based on
mixing speed and foam density. Due to the lack of variation in foam process and feel and
its consistent compressive modulus producing the smallest deviation, the PU foam V was
chosen as the baseline material. The foam layer must also be the proper balance between
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comfort and toughness to ensure patient compliance and resistance to large forces to the
foot.
Comparative Absorption Study
A comparative study was conducted to determine ideal absorption and wicking of
any kind as seen in Figure 3.5. Absorption and moisture wicking of the PU foam and three
different types of absorptive dressings were measured over 5 days with serum used as the
absorbate to best represent exudate viscosity. Results of this study showed that the PU foam
layer had comparable absorption to Aquacel® (Hydrofiber® technology) and Algicell®
(alginate-based dressing). The commercialized dressings exhibit an ideal removal of
remaining serum overtime, whereas our PU foam 5 seemed to saturate within 24 hours.
There is significant difference between the absorption profile of the PU foam layer and the
Hydrofera® dressing (p = 0.013). Although Hydrofera® is also composed of primarily PU,
it contains a surface additive, PVA that could explain higher initial absorption. That being
said, tuning the surface chemistry of the PU foam layer is necessary to initiate optimal
absorption.
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Figure 3.5: Serum absorption and moisture wicking of PU Foam V and commercialized
absorptive dressings.
UVO Treated Foam Swelling
PU foam V was exposed to UVO treatment for 15, 30, and 60 minutes. UVO
treatment radiates at 184.9 nm and 253.7 nm. The shortest wavelength dissociates polymer
chains on the surface in a process called photo-sensitized oxidation. Secondly, atomic
oxygen and ozone molecules formed in response to the longer wavelength oxidizes the
polymer surface forming peroxy and hydroxyl radicals, hydro-peroxide, carbonyl, and
carboxyl functionalities, all of which increase the surface wettability of the PU21. The
remainder of the PU foam beneath the surface remains unchanged.
Foams were introduced to water immediately after treatment, and the mass was
measured across a 7 day period. Figure 3.6 shows that after 30 minutes or more of UVO
exposure time, the initial percentage of swelling went up by approximately 20%. When
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looking at the final timepoint at 160 hours, the 30 minute UVO exposure wears off,
reaching a similar percent swelling than that of the control foam. There is, however, a 13%
difference between that of the control foam and 60 minute UVO exposure treatment.
Therefore, the 30 minute exposure treatment has the maximum effect on initial absorption,
but longer durations of UVO exposure indicates its longevity throughout later time points.

Figure 3.6: Percent swelling of UVO treated PU foams.
UVO Treated Water Contact Angle
Immediately after UVO exposure, 2 µL of H2O was dropped on a flat area of each
foam using a 2 mm diameter needle. Images, seen in Figure 3.7, were captured and the
angle was measured via Adobe Photoshop. The contact angle did not show any decrease in
angle after 15 minutes of exposure. However, after 30 minutes and 60 minutes, the angle
decreased by 11.8° and 33.05°, respectively.
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Figure 3.7: Contact angle measurements of PU foam (A) without UVO treatment, with
(B) 15, (C) 30, and (D) 60 minutes of UVO treatment.
Wicking analysis
In addition to absorption, vertical moisture wicking of the textile layer was
analyzed. A solution of pig serum with viscosity of approximately 1.6cP and blue dye was
used as the absorbate to mimic the viscosity of wound exudate. The vertical wicking rate
can be seen in Figure 3.8, where time is measured in seconds. The sample fabric was tested
three times. After an average of 1 minute and 5 seconds, the dyed serum reached the
boundary of the fabric. After vertically exposed to the serum solution, the 4DG, braided
layer was able to wick the serum upwards at an average wicking rate of 0.88 ± 0.265
millimeters per second. The vertical wicking rate tapers off at greater distances, indicating
a non-linear trend as seen in Figure 3.9.
.
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Figure 3.8: Time-capture (minutes:seconds) of vertical wicking using dyed porcine serum
through the 4DG channels of the braided PLLA yarn.

Figure 3.9: Average vertical wicking rate of serum through 4DG braided yarn
(n = 3; σ = 0.265 mm/sec)
Conclusions and Limitations
This work explored the absorptive and moisture wicking layers needed for
effectively managing overwhelmingly high exudate levels that is a common symptom in
diabetic chronic wounds. Among many different types of super-absorbent materials, PU
foam was chosen as the baseline material due to its versatility, tunability,
manufacturability, longevity, compression and comfort. With the addition of UVO

103

exposure, PU foam V showed optimal and comparable absorption to Hydrofera® and
initiated absorption more aggressively than other alginates and dressings with hydrofiber®
technology. The longer the exposure time, the smaller the contact angle is, and therefore,
the greater the surface wettability. To prevent saturation and maceration of the PU foam, a
braided wicking layer with fibers of 4DG cross sections was created. The microscopic
channels along the fiber was conducive to vertically and horizontally wicking away viscous
liquids, like that of wound exudate. Above the skin contact layer, we aim to manage
overwhelmingly high levels of moisture and exudate by distributing moisture throughout
the dressing so as not to produce maceration, absorbing moisture through the UVO treated
PU foam, and evaporating from the wicking layer to increase dressing longevity, while
preventing rapid saturation.
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CHAPTER FOUR
EVALUATING THE EFFICACY OF A MULTI-PHASIC WOUND DRESSING FOR
SIMULTANEOUS ANTIBACTERIAL ACTIVITY AND MOISTURE
MANAGEMENT IN AN IN VITRO DIABETIC WOUND MODEL
Introduction
Basic research in understanding the complex mechanisms underlying the changes
in inflammation and wound healing associated with diabetes and neuropathy currently
relies heavily on in vivo models1. Creating an alternate in vitro model that combines both
biofilm formation on epithelial tissue while affected by diabetic conditions remains
challenging to reproduce. Due to the complexities of replicating chronic inflammation,
most wound care research opts for in vivo wound modeling, such as murine or porcine
models, or even ex vivo models. However, this method proposes some ethical concerns
related to a lack of verification and validation testing before animal trials which lead to the
potential for animal subject waste and high expenses. The advantage of an in vitro model
reduces such ethical dilemmas, while promoting Russell and Burch’s ethical framework
regarding the “Three R’s” (Replacement, Reduction, and Refinement)2. It also allows
researchers to tightly control their variables surrounding an extracellular environment
while providing real time imagining and recording of complex intracellular pathways and
events1. For wound healing and diabetic models, in particular, there is a strong need for
implementing in vitro wound models for controlling and understanding key variables in
chronic inflammation, while reducing ethical concerns surrounding premature animal
trials.
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Wound Models
Skin makes up the largest organ in the body. It is multifunctional, acting as a barrier
from external harm, while regulating body temperature, providing water, hormones, and
insulation, and delivering various substances to injured areas so that it can fight off any
infection3. While versatile in function, the skin is composed of three distinct layers (Figure
4.1), each of which provide a unique purpose.

Figure 4.1: Illustration of skin comprised of its three distinct layers. [4]
The epidermis is the outermost layer composed of keratinocytes and corneocytes
that pack together to create a necessary barrier from the outside environment. These cells
constantly renew themselves in response to pressure or rubbing. The epidermis also
contains melanocytes that store melanin – a pigment that protects the skin from the sun’s
UV rays. Lymphocytes are also prevalent in the epidermis which have an important role in
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preventing infection. Finally, merkel cells are nerve cells that allow one to feel and sense
pressure5.
The dermis is the middle layer which is made up of dense, elastic collagen fibers.
It is the thickest of the three layers. Many nerve fibers and capillaries are present, allowing
nutrients and oxygen to pass into cells. Additionally, they help regulate body temperature
through the sweat glands6.
Finally, the subcutaneous fat is predominately made up of fat and connective tissue.
It acts as a shock absorber to protect bones and other organs. Many hormones, blood and
lymph vessels, sweat glands, sebaceous glands, scent glands, and hair roots are found in
this layer as well6.
There is a precise mechanism that occurs when there is destruction to any or all of
the three layers of the skin. This mechanism can be divided into five distinct phases:
hemostasis, inflammation, proliferation, repair, and remodeling7. Due to comorbidities and
other pathophysiological complications, such as diabetes mellitus, autoimmune disorders,
or genetic diseases, some wounds cannot properly heal themselves leading to chronic ulcer
formation, scars, keloids, and amputation or sepsis in severe cases8.
Proper research requires a model that considers the physiological components of
the three skin tissues as well as the atypical inflammatory response that may impede
healing. Many models have first looked into migration assays via a 2D cell monolayer
analysis. Some common 2D wound healing models involve scratch, stamping, thermal
wounding, electrical wounding, and optical wounding. However, many of these models are
difficult to exactly replicate causing variation in data acquisition. Due to the complexity of
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wound healing, especially in an immunocompromised environment, as well as the search
for advanced research, the 2D model has been overshadowed by 3D wound healing
models9.
3D cultures allow for a better representation of cell-matrix and cell-cell interactions
within the healing process. Many 3D models use various types of artificial skin or
dermatological testing. Other 3D elements consist of a dermis, comprised of hydrogels or
synthetic polymers, and an epidermis layer, comprised of keratinocytes10. Wounding then
consists of punch biopsies. Yet the methodology does not consider the lack of
reproducibility in procedure. Much of the 3D wound model is qualitative, examining the
immunohistochemistry and histology of the tissue. Some software can denote percent
healing by looking at the area of the wound size over time11.
Infection Models
The severity of infection can vary from patient to patient and can depend on the
significance of dysfunctional inflammatory response from diabetes and hyperglycemia as
well as the classification of the wound based on how early the ulcer was recognized.
Although there is some variation in infection, especially between the classification methods
as mentioned in Ch. 1, there is a need to create a standardized infection model to fully
examine the holistic effect on wound healing. As mentioned in Ch. 2, the largest proportion
of pathogens found in diabetic chronic wounds are Staphylococcus aureus, Enterococcus
faecalis, Pseudomonas aeruginosa 12,13. Bacteria can be cultured in liquid broth suspension
or on agar depending on the analysis required. Pathogens must be at a concentration that is
above or equal to 105 Colony Forming Units per gram in order for its presence to interfere
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with the wound healing process14. Once at a critical level, bacteria can coexist with each
other to create a poly-microbial aggregate, referred to as a biofilm15. The conglomerate of
microorganisms can allow for the exchange of metabolic products, such as pyocyanin, and
other reactive oxygen species (ROS) as well as the removal of toxic end products so that
they can sustain themselves against the immune cascade and antimicrobials16. The stages
of biofilm formation are (1) reversal attachment, (2) irreversible attachment, (3) maturation
and (4) dispersion as seen in Figure 4.215.

Figure 4.2: Schematic of the 4 distinct phases involved in biofilm formation.15
When the bacteria produces matrix polysaccharides, this can lead to severe
infection because the formation of a mucoid biofilm can tolerate antibiotics and
components of the innate and adaptive immune response, while resisting phagocytosis.
Examples of chronic inflammation and severe infection from biofilm formation are cystic
fibrosis and heavy dental plaque16.
Exudate Models
Previously mentioned in Ch. 3, one of the major complications in wound care is
managing wound exudate. Normal wound exudate levels are necessary for proper healing.
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At healthy levels, wound exudate provides essential nutrients and growth factors required
in the repair and remodeling phase of healing, while also preventing the wound bed from
drying out17,18. In chronic wounds, exudate levels contain higher concentrations of
MMPs19. MMP-2 and MMP-9 protein concentrations can often be 10-25 times higher in
chronic wounds20. When managing wound exudate, a physician assesses color, odor,
volume, viscosity, and whether it causes maceration of the surrounding wound area21,22.
Without proper treatment, exudate levels remain high while growth factors remain low,
ultimately hindering a proper healing response.
There are four types of wound exudate that are considered during wound
assessment. Serous drainage is clear, thin, and watery and can be a typical inflammatory
response. Too much of serous drainage can be a result of biofilm formation. Sanguineous
drainage may include blood leakage from a full- or partial-thickness wound. Sometimes it
can occur as a result of trauma. Purulent drainage is a thicker consistency and can vary in
color. Higher viscosities of drainage correlate with more severe cases of infection. Finally,
serosanguinous drainage is the most common type of exudate and can be described as thin,
pink, and watery23.
In vitro exudate models must consider ongoing production of exudate as well as the
viscosity that is most common for the wound of study. A standardized model must simulate
an ongoing and overwhelming level of exudate production that causes maceration of the
tissue, ultimately impeding healing. Some models can include wound fluid obtained
subcutaneously in dogs and mice. Others can include exudate from patient samples,
collected from wound VAC, a negative pressure wound therapy that removes excess
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exudate, while increasing the wound contraction rate24. A unique alternative approach can
also rely on blood plasma and serum, both of which are rich in many inflammatory and
clotting proteins.
Diabetic Models
As mentioned previously in Chapter 1, the pathophysiology of diabetes and its
comorbidities that include neuropathy and peripheral arterial diseases are complex and
difficult to model in vitro because of its reliance on vascular movement and leukocyte
migration, cytokine response, etc. Gardiner et al. asks the fundamental questions, “Can one
realistically expect to model such a complex, multifactorial disorder such as diabetic
neuropathy in a dish?”1 The simple answer is, probably not. But, by developing models
and enhancing such models, a window of opportunity arises that allows in vitro diabetes
research to become more of a realistic possibility.
There are many variables to consider when engineering an in vitro diabetic model,
such as hyperglycemia, hypoxia, high sorbitol and fructose accumulation, and oxidative
stress25-29. Many studies have investigated the effects of raised glucose on cells1. Others
have taken an alternative route by manipulating insulin concentration and function30,31. Yet,
there remains a secondary choice of how to derive the model, i.e. using cells derived from
healthy or diabetic rodents. Cells derived from healthy rodents might experience more of
an acute response to glucose levels, while diabetic rodents might have already developed
an alternative metabolic reaction to prolonged hyperglycemia. In regard to insulin,
controlling cell media is key. Cells from a healthy, control rodent might react to glucose
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levels and fluctuating insulin differently than from a diabetic rodent that spent several
months adapting to excess glucose and limited insulin1.
An alternative method to modeling a diabetic environment in vitro is by
investigating the role of intracellular oxidative stress using pro-oxidants such as hydrogen
peroxide (H2O2), lipid peroxidation products, oxidized LDLs, as well as serum or plasma
from diabetic subjects32-37.
Taking in consideration the variety of different variables when modeling a diabetic
environment, there remains many challenges and limitations. However, in the case of
neuropathy and wound healing, many aspects can be tested individually. Additionally,
results will be reported on a subcellular response, which can allow researchers to
understand more easily changes that contribute to ineffective wound healing. As the trend
towards in vitro diabetic modeling becomes more favorable for early verification analysis,
there will be more opportunity for future refinement and better outcomes when translating
to in vivo animal models and clinical trials.
Alternative Models
The most common research approach to modeling acute and chronic wounds are
animal models because of their availability and ease of handling. Additionally, many
animal models more closely represent that of the human inflammatory and immune
responses. Porcine models are common in cutaneous wound healing models because the
skin is the most anatomically and physiologically similar38,39. Porcine models can be
expensive, however, resulting in the vast majority choosing rodent models. Unlike porcine
models, rodent wound models have alternative healing mechanisms. Wound closure
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depends heavily on contraction, whereas in human wound healing, closure happens due to
re-epithelialization and granulation tissue formation40.
Because of the fundamental differences in animal models, human models of wound
healing are necessary to translate the significance of animal studies. Although some
researchers propose that personalized wound healing is a significant concern, a human
wound model contains the relatively similar pathology and physiology of healing as the
patient. There are several types of human models, and choosing the right one depends on
the research proposal. Partial thickness is simple and only considers the epidermis and
superficial dermis41. A blister model looks at the separation of the epidermis and dermis
caused by flooding of interstitial fluid. The abrasive wound model consists of inflicting
superficial abrasions by repeatedly corroding the skin with a surgical brush until bleeding
occurs42. This model is closely aligned with the realities of a superficial minor wound. It
also is a relatively reliable model for evaluating the healing properties of wound dressings.
Finally, full thickness wound models involve removing all of the epidermis and dermis,
and most of the subcutaneous fat, where it can disrupt dermal blood vessels. This can be
performed using a punch biopsy. Bleeding and fluid loss is more prominent in this model,
and the tissue can be prone to infection41. Depending on the wound model, healing can be
assessed by a combination of techniques, such as wound contraction rate, granulation tissue
formation, and histological analysis where cell populations and angiogenesis is observed.
Human wound models are typically limited to qualitative analysis and require expertise in
knowing what to look for. Therefore subjectivity and error by eye are common.
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There is no doubt that wound healing is a complex process to model. To date, there
isn’t one model that accurately represents the morphology and physiological reaction
occurring in acute and chronic wound healing. The correct steps must be performed,
however, before relying on animal and human subjects, to reduce cost and subject waste,
among other ethical concerns. Therefore, a standardized protocol incorporating a procedure
of in vitro analysis, animal testing, and human clinical trials must be practiced.
The objective of this aim is to design and develop a basic standardized in vitro
wound model that considers the cross-talk between healthy fibroblasts and P. aeruginosa
while measuring the efficacy of our multi-phasic medical textile wound dressing, all while
preventing premature animal testing. This model will adapt some of the work shown in
Price et al43. The substrate of our wound model will consist of a monolayer of P. aeruginosa
on a fine layer of agar that sits in a transwell insert. Beneath the insert will be a monolayer
of healthy fibroblast cells. The pores of the insert will be 0.4 µm to initiate a cross-talk
between both cell lines without direct contact. Vasculature will be artificially engineered
to deliver porcine serum using a 0.03 inch inner diameter perfluoralkoxy alkane (PFA) high
purity tube, used to mimic the constant production of wound exudate.
The timing element of the wound model is crucial to best replicate the stages of
inflammation in a diabetic chronic wound. Analysis of induced inflammation and wound
healing will take place over a period of 96 hours. A multi-level analysis will include
measuring moisture absorption and wicking, antibacterial efficacy, metabolic activity of
healthy fibroblast proliferation, and oxidative stress.
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Research Objectives
Specific research objectives for this work included the following items:
1. Design and develop an in vitro chronic wound model that combines a time sensitive
and concentration dependent co-culture of healthy fibroblast and P. aeruginosa
with the continuous supply of porcine serum
2. Incorporate each of the three layers together to create the multicomponent and
multiphasic medical textile wound dressing
3. Conduct a multi-level analysis that measures moisture absorption and wicking,
antibacterial efficacy, metabolic activity and cell proliferation of fibroblasts, and
oxidative stress of fibroblasts during phases of inflammation
Materials and Methods
Multiphasic Wound Dressing Preparation
The multi-layered medical textile wound dressing consists of a UVO treated
absorptive PU foam V layer, sandwiched between two woven PLLA yarn of 4DG
geometry, all wrapped around a gentamicin sulfate and polyethylene glycol incorporated,
knitted PLLA contact layer. Knitted contact layers were cut in 2 cm x 1 cm rectangles and
soaked in a solution of 100 µg/mL GS (Acros Organics, Thermo Fisher Scientific, Geel,
Belgium) and 40 mg/mL 1500 Da PEG (Sigma-Aldrich, St. Louis, MO USA) in sterile DI
H2O for 48 hours. At 48 hours, 1 cm x 1 cm x 0.1 cm PU foams V (Smooth-on Inc., East
Texas, PA) were exposed to UVO using a UV-Ozone cleaner (Novascan Technologies
Inc., Boon, IA USA) on each side for 60 minutes. PLLA braided layers were cut in 1 cm x
1 cm squares. Following UVO treatment, each of the layers were combined as seen in
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Figure 4.3 and dried overnight. Just prior to application, the mass of the wound dressing
was measured followed by UVO sterilization treatment for 30 minutes on each side.

Figure 4.3: Schematic of multi-component wound dressing and the appropriate functions
of each layer
In-vitro Model Preparation
Fibroblast Culture
Fibroblasts used in this study were from a murine 3T3 cell line. Cells were first
cultured in T-75 polystyrene culture flasks (Corning; Fisher Scientific, Waltham, MA,
USA) to confluency in a growth medium cocktail consisting of Dulbecco’s Modified
Eagles Medium (DMEM) (R&D Systems, Inc. Minneapolis, MN, USA), fetal bovine
serum (FBS) (Life Technologies, Carlsbad, CA, USA), and antibiotic-antimycotic (AA)
(Life Technologies, Carlsbad, CA USA) at 37°C and 5% CO2. Growth medium was
changed every two to three days. Cells were removed from their flask via trypsinization
and split into a 6-well plate (Corning; Fisher Scientific, Waltham, MA, USA) with the
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starting density of 17,000 cells/well. Media consisted of DMEM, 10% FBS, and 0.3% AA.
Fibroblasts were incubated for 24 hours.
Bacteria Culture
Using culture tubes, P. aeruginosa was inoculated in 3.5 mL of liquid broth (LB),
Lennox (Fisher Scientific, Fair Lawn, NJ) and incubated at 37°C and 5% CO2 overnight.
The culture tube was set on an agitator plate to prevent pellet formation while promoting
homogenous mixture of P. aeruginosa. After resuspension of bacterial solution, the starting
optical density (OD) was measured from the culture tube using a NanoDrop 2000
(ThermoFisher Scientific, Waltham, MA). The bacteria solution was diluted 1000-fold
using sterile LB. 1.25 mL of agar was added to each transwell insert (VWR, Radnor, PA)
following 24 hours of fibroblast culture. Three 1 mm pores were created in the agar to
stimulate bacteria movement throughout the insert. 36 µL of diluted P. aeruginosa was
added to the agar and set to incubate at 37°C and 5% CO2 overnight.
Vascular Model
A two foot PFA tubing high purity 1/16” OD x 0.030” ID, luer adapter, and
flangless fitting short (IDEX Health and Science, Bristol, CT) was soaked in ethanol
overnight. The PFA tubing was bent to fit on the bottom of the transwell insert. An
approximately 1/10” hole was drilled into the top of a 6-well plate lid to allow the tubing
to travel from the transwell to the syringe pump located outside of the incubator. Porcine
serum was thawed under UV overnight. After 24 hours of fibroblast and bacteria coculture, serum was added to a 5 mL syringe (Becton Dickinson and Company, Franklin
Lakes, NJ) and connected to the PFA tubing, luer adapter, and fitting short, and ultimately
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connected to a SyringeONE Programmable Syringe Pump (Darwin Microfluidics, Paris,
France). The starting pump rate was approximately 32 µL/hr and decreased by 5µL/hr
every 12 hours to simulate less exudate formation influenced by normal wound healing.
In vitro Model Analysis
After 48 hours of fibroblast and bacteria co-culture and serum administration,
dressings were added to their respective treatments. Measurements were taken every 12
hours between 48 and 96 hours. Figure 4.4 illustrates the wound model, composed of
fibroblasts cultured in the well, P. aeruginosa cultured on agar molded to the bottom of the
transwell insert, the PFA tube allowing serum to flow at a specified rate, and finally, the
dressing. Table 4.1 depicts each measurement taken at its specific time point to best
represent an ideal wound model.

Figure 4.4: (A) Schematic and (B) image of the in vitro wound model including the coculture of fibroblasts and P. aeruginosa, serum administration via tubing system, and
dressing.
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Table 4.1: Analysis schedule at particular time-points and treatments throughout wound model
• Fibroblasts

24 hours
✓Metabolic
Activity

48 hours
✓Metabolic
Activity

60 hours
✓Metabolic
Activity

72 hours
✓Metabolic
Activity

84 hours
✓Metabolic
Activity

96 hours
✓Metabolic
Activity

✓Oxidative
Stress

✓Oxidative
Stress
✓Metabolic
Activity

✓Oxidative
Stress
✓Metabolic
Activity

✓Oxidative
Stress
✓Metabolic
Activity

✓Oxidative
Stress
✓Metabolic
Activity

✓Oxidative
Stress
✓Metabolic
Activity

✓Oxidative
Stress

✓Oxidative
Stress

✓Oxidative
Stress

✓Oxidative
Stress

✓Oxidative
Stress

✓OD
✓Initial
mass of
dressing

✓OD
✓Metabolic
Activity

✓OD
✓Metabolic
Activity

✓OD
✓Metabolic
Activity

✓OD
✓Metabolic
Activity

✓Oxidative
Stress

✓Oxidative
Stress

✓Oxidative
Stress

✓Oxidative
Stress

✓OD

✓OD

✓OD

✓OD

✓ Mass of
dressing after
12 hour
administration
✓Metabolic
Activity

✓ Mass of
dressing after
24 hour
administration
✓Metabolic
Activity

✓ Mass of
dressing after
36 hour
administration
✓Metabolic
Activity

✓ Mass of
dressing after
48 hour
administration
✓Metabolic
Activity

✓Oxidative
Stress

✓Oxidative
Stress

✓Oxidative
Stress

✓Oxidative
Stress

✓OD

✓OD

✓OD

✓OD

✓ Mass of
dressing after
12 hour
administration

✓ Mass of
dressing after
24 hour
administration

✓ Mass of
dressing after
36 hour
administration

✓ Mass of
dressing after
48 hour
administration

• Fibroblasts
• Agar
• P. aeruginosa

• Fibroblasts
• Agar
• Dressing

• Fibroblasts
• Agar
• P. aeruginosa

• Serum
• Dressing

✓Initial
mass of
dressing

At each 12 hour time point, dressings and tubing with serum were removed.
Transwell inserts were separated from their respective well.
Absorption and Moisture Wicking
Immediately following disassembly, the mass of each dressing was measured. The
increase in weight percent was calculated using the initial and final mass of the dressing,
using Equation 3.1.
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Oxidative Stress Test
1 mL of media was collected from each well and frozen at -80ºC until analysis.
H2O2 levels of each treatment was measured using AmplexTM Red Hydrogen
Peroxide/Peroxidase Assay Kit (Thermo Fisher Scientific Life Technologies Corporation,
Eugene, OR). AmplexTM Red reagent (10-acetyl-3,7-dihydroxyphenoxazine) was thawed
to room temperature and diluted with 60 µL of Dimethyl Sulfoxide. Reaction buffer was
diluted 5-fold. Horseradish peroxidase (HRP) was dissolved using 1 mL of reaction buffer.
H2O2 was dissolved 45-fold and used as a stock solution. A standard curve of H2O2 was
created, as seen in Table 4.2 to determine the relationship between fluorescence and H2O2
concentration.

Table 4.2. Standard curve concentrations (mM) for H2O2 detection
Standard curve
concentrations

0

2

4

6

10

All samples were thawed and diluted by adding 1mL of reaction buffer. 100 µL of
each sample was added to a well of a black-bottom 96 well plate (Corning; Fisher
Scientific, Waltham, MA, USA). 100 µL of a solution containing 50 µL of AmplexTM Red
reagent, 100 µL of HRP stock solution and 4.85 mL of reaction buffer was added to each
well and incubated at 37°C and 5% CO2 for 30 minutes. The fluorescence was measured
at an excitation and emission wavelength of 545 nm and 590 nm, respectively.
Antibacterial Efficacy Analysis
250 µL of sterile LB was added to each transwell and incubated for 2 hours to
remove the attached bacteria from the agar plate. Samples of each treatment were collected
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and the OD was measured using NanoDrop 2000 (ThermoFischer Scientific, Waltham,
MA).
AlamarBlueTM Assay
Approximately 150 µL of AlamarBlueTM dye (Thermo Scientific Remel Inc.
Lenexa, KS) was added to each well and incubated at 37°C and 5% CO2 for three hours.
100 µL was taken from each well and added to a 96-well plate. The plate was read using a
Synergy MX Multi-Mode Reader at an excitation wavelength of 560 nm and an emission
wavelength of 590 nm.
MTT Assay
The remaining DMEM solution with AlamarBlueTM dye was removed and each
well was rinsed with 1 mL of 1X PBS. The PBS was then removed and 2.5 mL of media
was added followed by 1.1 mL solution of 2 mg/mL thiazolyl blue tetrazolium bromide.
The solution was then incubated at 37°C and 5% CO2 for four hours. 100 µL was taken
from each well and added to a 96-well plate. The plate was read using a Synergy MX MultiMode Reader at an absorbance wavelength of 590 nm.
Statistical Analysis
All analyses included three replications (n=4) and were analyzed using the T.Test
function using Microsoft Excel program and a level of significance, 𝛼, of 0.10.
Results and Discussion
Multi-layered wound dressing
This study aims to imitate a chronic inflammatory response via a basic in vitro
wound model. Preliminary studies considered the idea of using Matrigel as a substrate
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rather than agar. Fibroblasts were intended to grow on and within the gel in the transwell
insert, while the well contained a liquid suspension of P. aeruginosa. After several
prototypes, the Matrigel was an unfit choice for this model due to its temperature sensitivity
and fragile nature that had to withstand a PFA tubing system that supplied serum.
Therefore, the model was reversed to contain agar as the substrate that lies above a
monolayer of healthy fibroblasts in growth media. The timeline as well as the different
controls and treatments were carefully considered to best replicate wound, infection, and
exudate formation. During the first 24 hours, fibroblasts were cultured and allowed to
proliferate on their own to mimic superficial skin. At 24 hours, P. aeruginosa was
introduced to the model in a transwell insert to best represent infection and a cause for
oxidative stress to the fibroblasts. At 48 hours, a microchannel of porcine serum was built
into the model to simulate a proinflammatory response caused by exudate formation. It is
at this point, that the model is at its most chronic state, best representing a diabetic chronic
wound. At the same time, the multiphasic wound dressing is placed on the model to help
influence a normal inflammatory response, while initiating healing. In addition to the
model, a “control” well with just fibroblasts, an “infected, untreated model” of a co-culture
of fibroblasts and P. aeruginosa, a “dressing model” with fibroblasts, agar and the dressing
were assessed in order to control for healthy cell proliferation, fibroblasts’ response to
infection, and any potential adverse effects from the dressing, respectively. An image of
the antibacterial, non-adhesive and moisture absorptive medical textile dressing can be
seen in Figure 4.5.

124

Figure 4.5: Multilayered wound dressing showing the antibacterial and non-adhesive
PLLA skin contact layer on the outside, and a UVO treated PU foam layer sandwiched
between two 4DG moisture wicking and evaporative PLLA layers.
Absorption and Moisture Wicking Analysis
The increase in weight percent was calculated starting at hour 60 and every 12 hours
after, eventually reaching 96 hours. Both the dressing and wound model conditions were
treated with UVO to initiate moisture absorption. Due to the wound model absorbing serum
in addition to some of the media absorbed through the transwell with the agar, the weight
percent remained higher than the dressing condition up to hour 84, as seen in Figure 4.6.
Once the weight percent increased to about 250%, there appears to be a subtle saturation
point. However, this could be due to the fact that at this point (t=92 hours), serum levels
have saturated the absorptive layer causing the evaporative layer to wick away excess
moisture, and therefore slightly decreasing the weight percent. Additionally, the flow rate
of exudate decreased over time mimicking a healthy healing response which could also be
an indicator for a decrease in weight percent.
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Figure 4.6: Increase in weight percent (% x 100) of dressings for the dressing
and wound model treatments.
Antibacterial Efficacy
The optical density (OD) of each treatment was measured starting at hour 48 and
every 12 hours after, eventually reaching 96 hours, as seen in Figure 4.7. The time duration
between 24 and 48 hours represents the progression leading up to full infection prior to
treatment. The positive (bacteria + fibroblasts) and negative control (bacteria) increase
linearly up to 84 hours. The wound model showed a decrease in OD compared to positive
control, however after there is a subtle increasing trend in OD after 60 hours indicating
antibiotic “wear-off” or potential resistance. The OD of the dressing model that was
engineered without any presence of P. aeruginosa was also measured to control for any
change in turbidity from the agar or dressing. Although lower than both the infected model
and wound model, there was a subtle increase in OD up to 84 hours. This treatment is
important to set the baseline for OD, given the nature of the model. Since the wound model
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and dressing model show no significant difference, it can be concluded that with the
addition of the dressing, there remains effective antibacterial properties during this time
duration.

Figure 4.7: Antibacterial efficacy profile after administration of wound dressing.
Cell proliferation analysis via AlamarBlueTM and MTT Assays
This experiment not only looked at the potential for cell proliferation indicating
some repair and remodeling, but it tested the validity of the in vitro chronic wound model,
given the interaction of the co-culture of two very different cell lines. The cell metabolic
activity was measured via AlamarBlueTM fluorescent agent. Normalized metabolic activity
is described as the percent viability. Each experimental condition’s percent viability was
calculated using the fluorescent readings of the experimental condition and the control
condition, which included only the cultured 3T3 fibroblasts. The MTT assay measures
absorbance of each treatment after adding a set amount of tetrazolium dye that reduces
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when exposed to NADPH-dependent cellular oxidoreductase enzymes that transforms
viable cells into formazan crystals. The absorbance readings correlate to the amount of
formazan crystals present.
Figure 4.8 shows the percent viability and the metabolic activity of the total number
of cells exposed to a combination of agar, P. aeruginosa, serum, and/or the wound dressing.

Figure 4.8: (A) Percent viability (B) and metabolic activity of 3T3 fibroblasts exposed to
untreated infection, the wound dressing, and the treated wound model.
After the presence of bacteria between the hours of 24 and 48, there was expected
to be a decrease in cell viability due to the potential of induced oxidative stress from the
influence of P. aeruginosa. For both assays, there happened to show a slight increase in
viability. At 60 hours, there seems to be a consistent trend in an increase in viability for all
treatments, where the dressing model remains the highest in viability which could be due
to the lack of P. aeruginosa present. After 60 hours, the AlamarBlueTM assay appeared to
have a consistent trend where there was a slight decrease in viability for all treatments,
with the dressing having the highest viability at all time points. In the MTT assay
experiment, the treated wound model has the second highest viability at t=60 hours. At 72
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hours, there is a drop in viability in the infected model, relative to the control, dressing and
wound models for both experiments. At 84 hours, there seems to have a peak in absorbance
for the MTT assay, where the treated wound model and control have the highest
absorbance. The infected model appears to have increased between 72 and 84 hours,
surpassing the dressing model, although subtly. At 96 hours, there is a substantial decrease
in absorbance for the MTT assay. However, the wound model seems to have the highest
viability relative to other treatments.
There are some gaps in this particular analysis due to the limitations of the coculture as well as the cell viability assays. First, the DMEM media for which the fibroblasts
were cultured in needed an optimal dose of AA that allowed the cells to proliferate on their
own without killing the bacteria in the transwell insert. If the concentration of AA remained
too large, the media would diffuse through the pores of the transwell insert membrane and
agar and kill the bacteria immediately, which could act as a confounding variable for
inducing initial infection as well as the antibacterial efficacy analysis. If the concentration
of AA remained too small, fibroblasts would die off early on in the study due to handling
of the well area when adding agar and presence of infection, tubing, and/or exudate. Media
that contained 0.3% AA (30% the amount of what is normally used in cell-culture)
appeared to be an ideal condition for the co-culture. Secondly, it is assumed that both
AlamarBlueTM and MTT assays represented the viability of only the fibroblasts. Both
assays can measure certain cell health indicators such as plasma membrane integrity, DNA
synthesis and content, enzyme activity, and the presence of ATP, some of which are
markers for both eukaryotic and prokaryotic cells. The transwell insert membrane has
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microscopic pores of 0.4 µm. Pseudomonas measures 0.5-0.8 µm by 1.5-3.0 µm.
Therefore, it assumed that bacteria remained within the insert, while cell viability analysis
indicated fibroblast health.
Oxidative Stress Analysis
Oxidative stress of the 3T3 fibroblasts was measured via AmplexTM Red Peroxide
assay in support of the viability assays. As seen in Figure 4.9 there remains little to no H2O2
presence in each treatment, suggesting that oxidative stress in chronic and impaired wound
healing closely relates to phagocytic neutrophils and macrophages that utilize their reactive
and destructive properties. This is difficult to model in vitro and was omitted in this study44.
However, although relatively low in concentration, the H2O2 presence comes from the
combination of aerobic respiration from both the pseudomonas and fibroblasts.
Additionally, lower presence of H2O2 are expected in vitro when using a co-culture of only
two cell lines and at starting densities significantly lower than that of an in vivo model.
Oxidative stress occurs in all cell culture medium, especially as the media becomes limited
of serum and protein over time as the cells proliferate. Once the culture reaches confluency,
the oxidative stress can lead to cell apoptosis, protein modifications, and precipitation45,
which was consistent with results in Figure 4.8. Since the model consisted of relatively
higher cell viability, it is expected to see higher concentrations of H2O2 over time.
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Figure 4.9: Oxidative stress (H2O2) of 3T3 fibroblasts exposed to untreated infection and
the treated wound model.
Conclusions and Limitations
A large portion of this study focused on creating a reproducible and optimal in vitro
representation of a chronic wound that contained the combination of a superficial skin
component, infection, and exudate formation. While limited in its ability to reproduce
inflammatory cells and biproducts, this model illustrated the interaction between infection
and healthy fibroblast cells as well as the interference of high serum levels that mimicked
overwhelming exudated levels.
Following the invention of this model, the efficacy of the multiphasic wound
dressing was examined via antibacterial properties, moisture absorption, and healthy cell
proliferation. The dressing appeared to maintain inhibition of pseudomonas by a decrease
in growth between the ranges of 40% and 90% throughout the 48 hours of administration.
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The UVO treatment of the PU foam with the help of two moisture wicking layers
maintained absorption for 44 hours before implementing evaporative properties. Although
there appeared some inconsistency in trend when comparing treatment time points, there
is an overall upward profile of cell viability for both assays for the first 36 hours of
administration.
Most significantly, this study explored the efficacy of our multiphasic wound
dressing by looking at several variables simultaneously necessary for optimal chronic
wound healing without the need for premature animal and ex vivo modeling. There remains
some fine-tuning of both the model and the dressing, such as exploring the cross-talk
between biofilm formation and healthy fibroblast growth in an ideal growth media for both
cultures, and including other inflammatory cells and biproducts, such as leukocytes and
cytokines, as well as adjusting antimicrobial and adhesive properties for personalized
healing. Outcomes of this work suggest promise in the design and development of our
multiphasic wound dressing and its ability to stop and prevent infection, absorb excess
moisture, and promote the start of cell proliferation for repair and remodeling.
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CHAPTER FIVE
CONCLUSIONS
After several consultations and shadowing visits at the Prisma Health Wound Care
and Hyperbaric Center and an in-depth review of literature, it can be concluded that are
significant gaps when treating diabetic chronic wounds due to the lack of awareness and
early diagnoses, personalized healing, physician subjectivity when classifying a wound,
and most importantly the lack in holistic approach to healing by addressing the key features
of the T.I.M.E principle. Wound dressings have evolved over the course of a few decades
and based on recent literature, there is promise in their ability to address more than one
function of proper healing. This work focused on developing a cross-functional wound
dressing that addresses infection management, moisture absorption, and non-adhesion to
initiate wound repair and remodeling in chronic wounds. In this situation, successful
wound healing requires all key elements, and therefore the omission of one function is no
better than having none at all.
Specifically, this work focused on developing a multiphasic medical textile wound
dressing that includes an antibacterial and non-adhesive skin-contact layer, an absorptive
foam layer, and a moisture wicking and evaporative layer. In the first aim, the effect of
fiber geometry and antibacterial incorporation into the fiber was explored. Although the
release profile of gentamicin sulfate (GS) exhibited a burst release followed by an
exponential decay due to lack of binding affinity between the GS molecule and the poly-llactide (PLLA) yarn, the release profile was sufficient enough to kill and prevent further
growth of pseudomonas for up to five days by showing bactericidal and bacteriostatic
trends, respectively. This aim also addressed the need to prevent adhesion to fragile
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granulation tissue causing unnecessary autolytic debridement upon dressing changes.
Polyethylene glycol (PEG) was added as a microscopically thin surface layer and exhibited
significantly less fibroblast attachment. It can also be concluded that the addition of the
surface layer did not alter the antibacterial efficacy profile.
In aim 2, the combination of two medical textile wicking layers and a polyurethane
(PU) foam layer showed effective moisture management in order to address the need to
eliminate unwanted and overwhelmingly high levels of exudate. The unique design of a 4deep grooved (4DG) fiber cross-section provided channels along the fibers of the yarn to
vertically wick viscous liquids at a rapid rate for the purpose of distributing exudate across
the dressing to prevent maceration while evaporating into the external environment. In
between the wicking layers lies the PU foam layer used as an absorptive layer. To initiate
moisture absorption, the foam was exposed to ultra-violet ozone (UVO), and it can be
concluded that after 30 minutes of exposure, the PU reaches its maximum potential for
initiating absorption. On the caveat, higher exposure times increases the longevity of
moisture absorption. As the foam layer becomes saturated, the external textile-based
wicking layer serves as a secondary source of removing moisture from the foam.
After each layer of the wound dressing was evaluated separately, a novel in vitro
wound model was engineered to test the holistic approach to healing when each of the
layers were combined. As mentioned in Ch. 4, there are very few studies that have tested
the efficacy of wound dressings using an in vitro model due to the challenges of replicating
chronic inflammation, diabetes, and its comorbidities. Despite the obstacle, it is imperative
to explore many advantages of an in vitro model, such as reducing many ethical concerns
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regarding premature in vivo testing, animal waste, and expense while controlling few
variables within a healing response at one time. In this aim, healthy fibroblast cells were
infected with Pseudomonas aeruginosa in a co-culture model alongside a unique
microtubing system that supplied exudate to effectively analyze the combinational wound
healing approach of the multicomponent wound dressing. It can be concluded that the
growth of P. aeruginosa was inhibited by 40% - 90% at each time point. There was an
initial increase in weight percent (150%) after the first 12 hours of administration, followed
by a positive semi-linear trend at each of the following time points. This finding supports
the combination of the absorptive and wicking layers to effectively eliminate high exudate
levels without causing dressing saturation, and therefore increasing the longevity of the
dressing. Although there were some limitations with metabolic activity analysis assays due
to major assumptions of the model, we can conclude that the dressing is compatible to
healthy fibroblast proliferation, which is also consistent to preliminary findings in Ch. 2.
This work confirmed that the idea of creating a multicomponent dressing using the
combination of medical textiles and absorptive biomaterials shows promise for promoting
wound healing for complicated diabetic chronic wounds. The combination of antibacterial,
non-adhesion, absorption, and moisture wicking properties work together as a team to
simultaneously reduce infection, eliminate moisture, and promote wound repair without
unnecessary debridement. Together, multi-scale geometry, antibiotic release, and fluid
management are required in a next-generation textile-based biomaterial dressing to
effectively influence a healthy inflammatory response in some of the most chronic wounds
significantly prevalent in our country.
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CHAPTER SIX
RECOMMENDATIONS FOR FUTURE WORK
Although each chapter more specifically explains future directions for each
objective, this chapter highlights upcoming ideas and opportunities for improvements of
the wound dressing and in vitro wound model.
General considerations for the project include exploring methods for product
sterilization and ease for manufacturing. Sterilization must ensure an aseptic material
without interrupting the efficacy of the dressing, such as antibiotic activity and nonadhesion. Manufacturing should be considered throughout future work to ensure
reproducibility and efficiency.
Chapter 1.
1. With the exception of broad terminology in patent research and non-woven
materials, current literature lacks documentation of woven medical grade,
synthetic polymers incorporated with antimicrobials or growth factors. This
addition would greatly reduce expense and time required for melt-spinning
different biopolymers.
2.

This review lacks an extensive exploration in verifying wound care products,
particularly in vitro. As mentioned previously, most researchers opt for ex vivo
or in vivo animal or clinical studies, however there is very little movement in
controlling few inflammatory variables at one time via in vitro wound
modeling.
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Chapter 2.
1. Although methylene blue can cause minor cosmetic nuances, the structure of
the dye is a bit more 2D, relative to gentamicin sulfate, and therefore might
easily diffuse further into the fibers causing a longer lasting release. There is no
guarantee, however, that methylene blue will create a similar antibacterial
efficacy profile as GS.
2. The polyethylene glycol surface treatment was confirmed through X-Ray
photoelectron spectroscopy; however, experiments can expand beyond the two
MWs chosen for this study, to confirm ideal non-adhesion.
Chapter 3.
1. A more thorough analysis can be conducted to explore the physical chemistry
that occurs during the foaming process of polyurethane, as well as looking into
different densities and chemical and physical blowing agents that can alter the
feel, compression, and comfort of the foam.
2. Although compression measurements were conducted, mechanical toughness
and durability of the foam material could be evaluated against orthotics and
weight bearing activities.
3. As mentioned in the above chapter, 4DG fibers can weaken the tensile
properties. Different materials and weave design could be explored to consider
ease for manufacturing.
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Chapter 4.
1. The co-culture of the in vitro wound model that involved fibroblasts and
pseudomonas remained a challenge, especially when evaluating fibroblast
viability and proliferation. A more in-depth search into using a more ideal
media and substrate is needed for effective analysis.
2. Although this model is unique due to the addition of the microtubing system
to supply porcine serum as wound exudate, an advanced system with several
channels could be explored and designed to best mimic vasculature.
3. After a completed and confirmed in vitro analysis, the efficacy of the wound
dressing can be measured using ex vivo skin samples from donor pigs which
would include pro-inflammatory mediators.
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